healthevidencedigest

Blog

  • Ruxolitinib Has Worked for 15 Years. Now You Can Take It Once Instead of Twice a Day. Here Is What the Jakafi XR Approval Means in Practice.

    Ruxolitinib Has Worked for 15 Years. Now You Can Take It Once Instead of Twice a Day. Here Is What the Jakafi XR Approval Means in Practice.

    📌 The essentials On May 1, 2026, the FDA approved Jakafi XR (ruxolitinib, Incyte), a once-daily extended-release formulation of ruxolitinib, for the same four indications as the original Jakafi: intermediate- or high-risk myelofibrosis (MF) in adults, polycythemia vera (PV) in adults with inadequate response to or intolerance of hydroxyurea, steroid-refractory acute graft-versus-host disease (GVHD) in adults and pediatric patients aged 12 and older, and chronic GVHD after failure of 1 or 2 lines of systemic therapy in adults and pediatric patients aged 12 and older. This is a new dosage form approval, not a new indication. The indications are identical to the original Jakafi. The clinical basis: a randomized, open-label, 2-period, 2-way crossover bioequivalence study (NCT06555081) in 169 healthy adults, showing that 55 mg Jakafi XR once daily is bioequivalent to 25 mg Jakafi twice daily based on steady-state pharmacokinetic measures. Results presented as an ASH 2025 poster (Gong et al. Blood. 2025;146(suppl 1):5045). Safety of Jakafi XR is established from the extensive controlled studies of the original Jakafi across all approved indications: no new safety signals. Available for pharmacy orders beginning May 8, 2026. Critical practical note: Jakafi XR is not a new drug. It delivers the same ruxolitinib molecule at equivalent systemic exposure in a single daily tablet instead of two. Patients who switch should not expect a different clinical effect; the therapeutic benefit comes from the same mechanism and the same total daily drug exposure.

    Patients with myelofibrosis, polycythemia vera, and graft-versus-host disease have been managing chronic conditions for years on a twice-daily regimen. Twice daily means twice daily: morning and evening, 12 hours apart, building those doses into the rhythm of every single day. For patients who are also managing multiple comorbidities with multiple medications, that twice-daily requirement is one of many adherence demands that can compound into a real burden over time.

    On May 1, 2026, the FDA approved Jakafi XR (ruxolitinib), a once-daily extended-release formulation of a drug that has been the standard of care for myelofibrosis and polycythemia vera since 2011 and for steroid-refractory GVHD since 2019 and 2021. The clinical evidence behind the original Jakafi is unchanged. The new formulation simply delivers the same drug at equivalent systemic exposure in a single morning tablet.

    This is not a clinical advance in the sense of a new drug with new efficacy data. It is a formulation advance, removing one daily dose from the schedule of patients who are likely to be on this drug for years.

    What Ruxolitinib Is and Why These Three Conditions Require Long-Term Treatment

    Ruxolitinib is a selective inhibitor of Janus kinase 1 (JAK1) and JAK2, two enzymes that are central to the signaling pathways mediating inflammatory cytokine responses and hematopoietic cell proliferation. JAK1 and JAK2 mediate signaling from multiple cytokine receptors, and their overactivation is the pathological driver in myelofibrosis, polycythemia vera, and GVHD through distinct but related mechanisms.

    Understanding why patients take ruxolitinib for extended periods requires understanding each of the conditions it treats.

    Myelofibrosis

    Myelofibrosis is a myeloproliferative neoplasm in which progressive bone marrow scarring (fibrosis) disrupts normal blood cell production. The fibrosis is driven by inflammatory cytokine overproduction mediated in large part through JAK-STAT pathway activation, often involving somatic mutations in JAK2, CALR, or MPL. The result is progressive anemia, enlargement of the spleen (splenomegaly), constitutional symptoms including debilitating fatigue, night sweats, and weight loss, and over time, the risk of transformation to acute leukemia.

    Ruxolitinib was the first approved therapy to substantially reduce splenomegaly and improve constitutional symptoms in intermediate- and high-risk MF. It does not typically reverse or halt fibrosis progression, but it durably reduces the inflammatory burden that drives many of the disease’s most disabling manifestations. Most patients with MF who respond to ruxolitinib continue it indefinitely, as disease symptoms return on discontinuation.

    Polycythemia vera

    Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by overproduction of red blood cells, often accompanied by elevated white blood cells and platelets, driven almost universally by the JAK2 V617F mutation. The primary risk is thrombosis: the abnormally high blood cell counts and viscosity substantially elevate the risk of stroke, deep vein thrombosis, pulmonary embolism, and other thrombotic events. First-line management involves phlebotomy and aspirin for low-risk patients, and hydroxyurea for high-risk patients. Ruxolitinib is indicated for patients who have had an inadequate response to or are intolerant of hydroxyurea, providing JAK2-targeted suppression of the malignant clone. Again, this is chronic therapy: patients who achieve hematocrit control and symptom relief on ruxolitinib continue it as long as it is effective and tolerated.

    Graft-versus-host disease

    GVHD is a complication of allogeneic stem cell transplantation in which donor immune cells attack the recipient’s tissues. Acute GVHD typically involves the skin, liver, and gastrointestinal tract; chronic GVHD can affect virtually any organ system and is associated with significant morbidity and mortality. Ruxolitinib, by inhibiting JAK-mediated inflammatory cytokine signaling in donor T cells, reduces the inflammatory cascade driving tissue damage. GVHD patients may require treatment for months to years, again placing this in the category of chronic therapy where dosing schedule matters.

    Why a once-daily formulation matters for chronic blood disease management Patients with MF, PV, and GVHD are frequently older adults with multiple conditions managing multiple daily medications. They may also be managing disease symptoms including fatigue, pain, and cytopenias that affect daily function. In this context, the psychosocial and practical dimension of medication burden is well-documented: adherence to twice-daily regimens is consistently lower than once-daily regimens across all chronic disease areas, even when patients understand the clinical importance of each dose. Studies in conditions from hypertension to HIV have shown that reducing dosing frequency from twice daily to once daily improves adherence by 10 to 20%, with downstream improvements in outcomes that compound over years of treatment. For a drug that works as long as it is taken and loses its effect when stopped, that adherence difference is clinically meaningful.

    The Approval Basis: What Bioequivalence Means and Why It Is the Right Standard Here

    The FDA approved Jakafi XR based on a bioequivalence study, not on a new Phase 3 efficacy trial. This is the correct regulatory approach for a new dosage form of an existing drug with well-established efficacy and safety. Understanding why requires understanding what bioequivalence means and what it does not.

    What the bioequivalence study showed

    The pivotal study (NCT06555081) was a randomized, open-label, 2-period, 2-way crossover study in 169 healthy adult participants. Each participant received both Jakafi XR 55 mg once daily and Jakafi 25 mg twice daily in random order, with a washout period between. The study measured key pharmacokinetic parameters at steady state: AUC (area under the concentration-time curve, measuring total drug exposure) and Cmax (peak drug concentration).

    The FDA’s standard for bioequivalence requires that the 90% confidence interval for the ratio of the test (XR) to reference (IR) geometric means for AUC and Cmax falls within 80 to 125%. Jakafi XR met these criteria, confirming that the once-daily extended-release formulation delivers the same total daily ruxolitinib exposure as the twice-daily immediate-release formulation.

    Results were presented at the 2025 American Society of Hematology Annual Meeting (ASH 2025) in a poster by Gong et al. (Blood. 2025;146(suppl 1):5045).

    Pharmacokinetic differences between XR and IR: what matters clinically The extended-release mechanism produces a different concentration-time profile than immediate release, even when total daily exposure is equivalent. Jakafi IR produces two peak concentrations per day (one after each dose) with a trough in between. Jakafi XR produces a single, broader, lower peak with more consistent drug levels throughout the 24-hour dosing interval. For JAK inhibition, which requires sustained target coverage rather than intermittent high-concentration peaks, the flatter pharmacokinetic profile of once-daily XR is biologically appropriate. The trough concentrations between IR doses might theoretically allow partial JAK pathway reactivation; the XR formulation maintains steadier JAK inhibition. Whether this translates into any measurable clinical difference in efficacy or tolerability is not yet established from comparative clinical trial data, but the pharmacological rationale supports the XR approach.

    Why no new Phase 3 trial was required

    Ruxolitinib has been studied in multiple large Phase 3 trials across all approved indications, involving thousands of patients with substantial follow-up. The COMFORT-I and COMFORT-II trials established its efficacy in MF; RESPONSE trials established its efficacy in PV; REACH2 and REACH3 established its efficacy in acute and chronic GVHD respectively. Requiring a new Phase 3 trial to approve a formulation change that delivers identical drug exposure would delay access to the more convenient dosing form without generating scientifically useful information. The FDA’s bioequivalence pathway is precisely designed for this scenario.

    The Full Jakafi/Jakafi XR Approved Indication Picture

    Both Jakafi (original, twice daily) and Jakafi XR (extended release, once daily) now carry the same four indications:

    IndicationPopulation
    Intermediate- or high-risk myelofibrosis (primary MF, post-PV MF, post-ET MF)Adults
    Polycythemia vera with inadequate response to or intolerance of hydroxyureaAdults
    Steroid-refractory acute GVHDAdults and pediatric patients aged 12 and older
    Chronic GVHD after failure of 1 or 2 lines of systemic therapyAdults and pediatric patients aged 12 and older

    Jakafi XR is not approved for use in children with MF or PV; the MF and PV indications are adults only, identical to the original formulation. The GVHD indications cover pediatric patients aged 12 and older with the same weight and age constraints as the original formulation.

    Safety: What Applies to Jakafi XR

    Because Jakafi XR delivers the same drug at the same systemic exposure, its safety profile is established from the extensive clinical trial database of the original Jakafi across all approved indications. There are no new safety signals from Jakafi XR; the known adverse event profile of ruxolitinib applies in full.

    Most important safety considerations for prescribers and patients:

    Cytopenias: Thrombocytopenia, anemia, and neutropenia are the most common adverse reactions and can be severe. Dose adjustment or temporary interruption may be required based on complete blood count results. Monitoring is required before initiating and regularly during treatment.

    Serious infections: Ruxolitinib increases the risk of serious bacterial, mycobacterial, fungal, and viral infections. Tuberculosis reactivation has been reported. Patients should be evaluated for TB before starting treatment. Progressive multifocal leukoencephalopathy (PML), a serious brain infection caused by JC virus, has been reported rarely with ruxolitinib. Monitoring for signs and symptoms of new neurological symptoms is important.

    Herpes zoster: Reactivation of varicella zoster virus (shingles) occurs at higher rates with ruxolitinib than with many other agents. Varicella zoster vaccination before initiating treatment is recommended where possible.

    Second primary malignancies: Non-melanoma skin cancers and lymphomas have been reported. Periodic skin examinations are recommended.

    Lipid elevations: Increases in cholesterol, LDL, and triglycerides have been reported. Assess lipid levels approximately 8 to 12 weeks after initiating treatment.

    Symptom exacerbation on discontinuation: Abrupt discontinuation or dose reduction of ruxolitinib in MF patients can cause rapid return of splenomegaly, constitutional symptoms, and in rare cases a syndrome resembling hemophagocytic lymphohistiocytosis (HLH). Dose tapering is recommended when discontinuation is necessary.

    Boxed warning: The FDA requires a boxed warning for thrombosis including fatal cases and for serious infections. These risks apply identically to Jakafi XR as to the original Jakafi.

    Dosing: The Key Dose Correspondence Table

    Jakafi XR doses correspond to Jakafi (immediate-release) doses at a 2.2:1 ratio reflecting the once-daily to twice-daily conversion. The standard approved correspondence is:

    Jakafi XR (once daily)Equivalent Jakafi IR doseClinical context
    55 mg once daily25 mg twice dailyStandard MF/PV dose; bioequivalence study dose
    Other XR dosesCorresponding IR twice-daily dosesPer prescribing information; dose adjustments mirror IR guidance

    Administration: Take Jakafi XR orally once daily at approximately the same time each day, with or without food. Swallow tablets whole; do not crush, chew, or split. If a dose is missed, take it as soon as possible on the same day; if the next day has arrived, skip the missed dose.

    Switching from Jakafi IR to Jakafi XR: Patients who are stable on Jakafi IR can switch to the corresponding Jakafi XR dose. No dose change is required; the XR dose that matches their current total daily IR exposure should be used. Because switching does not change drug exposure, no transition period or observation period beyond clinical routine is needed.

    Practical Implications: Who Benefits Most From the Switch

    Not every patient currently on Jakafi needs to switch to Jakafi XR. The clinical effect will be the same. The question is whether once-daily dosing offers enough practical benefit for a given patient to justify the conversation with their hematologist and the pharmacy change.

    Most likely to benefit from switching:

    • Patients who find twice-daily adherence difficult due to variable daily schedules, work constraints, or fatigue affecting evening dose reliability
    • Patients who are managing multiple twice-daily medications and for whom consolidating to once-daily simplifies overall regimen complexity
    • Newly initiating patients for whom once-daily is operationally simpler than twice-daily from the outset
    • Patients who have expressed frustration with the twice-daily scheduling burden to their hematologist

    Unlikely to need switching:

    • Patients who are well-established on Jakafi IR with no adherence concerns
    • Patients for whom the twice-daily timing provides useful structure or reminders anchored to established daily routines

    The key message for patients and clinicians is that Jakafi XR is not a better drug than Jakafi. It is the same drug with a more convenient schedule. In a chronic condition where medication duration is measured in years, a more convenient schedule is a genuine quality-of-life improvement for patients who want it.

    For related HED coverage of other formulation advances improving treatment convenience in chronic conditions, see our post on Awiqli, the first once-weekly basal insulin, which similarly reduced the injection frequency from 365 times per year to 52 for appropriate patients with type 2 diabetes.

    Sources

    FDA approval announcement: FDA approves ruxolitinib extended-release tablets (Jakafi XR). FDA.gov. May 1, 2026.

    Incyte press release: Incyte Announces FDA Approval of Jakafi XR (ruxolitinib) Extended-Release Tablets. businesswire.com. May 1, 2026.

    Drugs.com approval news: Incyte Announces FDA Approval of Jakafi XR for Myelofibrosis, Polycythemia Vera and GVHD. drugs.com. May 2026.

    OncLive clinical coverage: FDA Clears Once-Daily Ruxolitinib Tablets for Myelofibrosis, Polycythemia Vera, and GVHD. onclive.com. May 2026.

    Targeted Oncology coverage: FDA Approves Extended-Release Ruxolitinib Once-Daily for MPNs and GVHD. targetedonc.com. May 2026.

    Cancer Therapy Advisor clinical review: Jakafi XR Approved for Myelofibrosis, Polycythemia Vera, and GVHD. cancertherapyadvisor.com. May 2026.

    CancerNetwork: FDA Approves Ruxolitinib Tablets for Hematologic Malignancies. cancernetwork.com. May 2026.

    CURE magazine coverage: FDA Approves Once-Daily Jakafi XR for Myelofibrosis and Other Conditions. curetoday.com. May 2026.

    Hematology Advisor: Jakafi XR Approved for Myelofibrosis, Polycythemia Vera, and GVHD. hematologyadvisor.com. May 2026.

    ASH 2025 bioequivalence poster: Gong X, Xun Z, Getsy J, McGee R, Mondick J, Punwani N. Bioequivalence of ruxolitinib once-daily extended-release vs twice-daily immediate-release tablets in healthy adults. Blood. 2025;146(suppl 1):5045. doi:10.1182/blood-2025-5045

    Bioequivalence study registration: NCT06555081. ClinicalTrials.gov.

    Jakafi original FDA approval (2011): FDA approves ruxolitinib for myelofibrosis. FDA.gov. November 2011.

    Jakafi prescribing information: Jakafi XR (ruxolitinib) Prescribing Information. Incyte Corporation. 2026.

    FDA bioequivalence guidance: Bioequivalence Studies with Pharmacokinetic Endpoints. FDA.gov.

    Ruxolitinib mechanism overview: Ruxolitinib. StatPearls. NCBI.

    JAK-STAT pathway in MPNs: JAK-STAT Pathway in Myeloproliferative Neoplasms. PMC4207474.

    MF cancer overview: Myelofibrosis. American Cancer Society.

    PV overview: Polycythemia Vera. NHLBI.

    GVHD overview: GVHD Fact Sheet. NCI.

    Patient resources: MPN Research Foundation | Leukemia and Lymphoma Society: Myelofibrosis | National MPN Advocacy and Education | Bone Marrow Transplant Info Network

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about switching from Jakafi to Jakafi XR, or initiating ruxolitinib therapy in any approved indication, should be made in consultation with a qualified hematologist familiar with the patient’s full clinical history, current blood counts, and concurrent medications. Do not discontinue or change ruxolitinib doses without medical guidance.
  • A Rare Bile Duct Cancer Defined by a Single Gene Fusion Just Got Its First Approved Targeted Therapy. Here Is What Bizengri Is and What the eNRGy Trial Shows.

    A Rare Bile Duct Cancer Defined by a Single Gene Fusion Just Got Its First Approved Targeted Therapy. Here Is What Bizengri Is and What the eNRGy Trial Shows.

    📌 The essentials On May 8, 2026, the FDA approved Bizengri (zenocutuzumab-zbco, Partner Therapeutics) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. This is the first FDA-approved targeted therapy specifically for NRG1 fusion-positive (NRG1+) cholangiocarcinoma. Bizengri’s third approved indication: it was previously approved in December 2024 for NRG1+ non-small cell lung cancer and NRG1+ pancreatic adenocarcinoma. Bizengri is now the only approved therapy for NRG1+ solid tumors across three different cancer types. The approval was expedited by a Commissioner’s National Priority Voucher (CNPV), awarded May 6, 2026 and used to compress the review timeline. The clinical basis: Phase 1/2 eNRGy trial (NCT02912949), cholangiocarcinoma cohort of 19 evaluable patients. ORR: 36.8% (95% CI 16.3 to 61.6%). Duration of response: 2.8 to 12.9 months. Regulatory designations: Breakthrough Therapy Designation (October 2025), Orphan Drug Designation (February 2026). Critical testing requirement: NRG1 fusions must be detected using comprehensive molecular testing, specifically tissue-based RNA sequencing, to reliably identify eligible patients. DNA-based testing alone may miss NRG1 fusions. Dosing: 750 mg IV every 2 weeks.

    Cholangiocarcinoma, commonly called bile duct cancer, is an aggressive malignancy arising from the epithelial cells lining the bile ducts. It is rare, accounting for approximately 3% of all gastrointestinal cancers globally, but deadly: the five-year survival rate for metastatic disease is below 10%, and most patients are diagnosed at stages where surgery is not possible.

    The treatment landscape for cholangiocarcinoma has evolved rapidly in recent years. Several actionable molecular targets have been identified in subsets of the disease, including FGFR2 fusions, IDH1 mutations, BRAF V600E mutations, HER2 amplification, and now NRG1 fusions. Each molecular subset represents a small fraction of the total cholangiocarcinoma population, but targeted therapy for each has produced response rates substantially higher than chemotherapy alone in those patients who carry the specific molecular alteration.

    On May 8, 2026, patients with NRG1 fusion-positive cholangiocarcinoma gained their first approved targeted option. Bizengri (zenocutuzumab-zbco), a bispecific antibody targeting HER2 and HER3, was approved based on a 36.8% objective response rate in 19 evaluable patients in the eNRGy trial cholangiocarcinoma cohort. In a disease with no prior approved targeted therapy for this molecular subset, that number represents a clinically meaningful new option for a population that has had very few.

    What NRG1 Fusions Are and Why They Matter Across Multiple Cancers

    To understand why Bizengri works across NSCLC, pancreatic cancer, and now cholangiocarcinoma, it helps to understand what an NRG1 fusion is and what biological pathway it activates.

    The NRG1 gene and neuregulin signaling

    NRG1 (neuregulin 1) encodes a family of growth factor proteins called neuregulins that are ligands for HER3 (ErbB3), a member of the HER receptor tyrosine kinase family. When neuregulin 1 binds HER3, it triggers HER3 to heterodimerize preferentially with HER2 (ErbB2), forming a signaling complex that activates downstream proliferation and survival pathways including PI3K/AKT and MAPK/ERK.

    In normal tissue, NRG1 signaling through HER3/HER2 is tightly regulated and context-dependent. In cancers with NRG1 gene fusions, the NRG1 coding sequence is joined to the sequence of a partner gene, creating a fusion protein that is expressed at abnormally high levels, constitutively activates HER3/HER2 signaling, and drives cancer cell proliferation in a fusion-dependent manner.

    NRG1 fusions are found across multiple solid tumor types but are rare in each individual cancer: prevalence estimates of approximately 0.2% of all solid tumors, with higher rates in certain histologies. In cholangiocarcinoma, NRG1 fusions are estimated to occur in approximately 1 to 2% of cases, representing a very small molecular subset of an already rare cancer. In the United States, this translates to only a few hundred patients per year.

    The testing challenge: why DNA sequencing alone may miss NRG1 fusions NRG1 fusions are gene rearrangements that join introns of two different genes. Because the fused protein is produced from the rearranged mRNA rather than from a simple point mutation or small insertion/deletion, RNA-based sequencing (which reads transcribed mRNA) detects NRG1 fusions more reliably than standard DNA-based next-generation sequencing. Partner Therapeutics specifically noted in the approval documentation that comprehensive molecular testing, particularly tissue-based RNA sequencing, is essential to reliably detect NRG1 fusions and identify eligible patients. Oncologists managing cholangiocarcinoma patients should ensure that their molecular profiling platform includes RNA-based fusion detection, as DNA sequencing alone may produce false-negative results. This is a critical testing consideration that distinguishes NRG1 fusion detection from some other molecular targets in oncology.

    What Zenocutuzumab Is and How It Works

    Zenocutuzumab (brand name Bizengri) is a bispecific antibody, meaning it is engineered to bind two different molecular targets simultaneously. Specifically, it targets both HER2 and HER3 simultaneously using a single antibody molecule. This dual targeting is the key to its mechanism in NRG1 fusion-positive tumors.

    The mechanism of action exploits a specific vulnerability in NRG1 fusion-driven cancer cells:

    In NRG1+ tumors, the fusion protein acts as an overexpressed HER3 ligand, continuously stimulating HER3 on the cancer cell surface to heterodimerize with HER2. Zenocutuzumab blocks this process by binding both HER3 and HER2 simultaneously: its HER3-binding arm prevents the NRG1 fusion protein from docking with HER3, while its HER2-binding arm prevents HER2 from forming its signaling-competent heterodimer with HER3. The result is that the constitutive NRG1 fusion-driven HER3/HER2 signaling loop is interrupted at two points simultaneously.

    This dual blockade strategy is mechanistically rational for NRG1 fusion-driven tumors in a way that single-target approaches are not. Blocking only HER3 might be insufficient if HER2 can still be activated by other means; blocking both removes the substrate and the dimerization partner of the constitutively active signaling complex.

    Zenocutuzumab does not work in tumors where HER2/HER3 signaling is activated by HER2 gene amplification or overexpression rather than NRG1 fusion. Its mechanism requires the NRG1 fusion to be the driver. This is why patient selection by molecular testing is not optional but essential for appropriate use.

    Bizengri’s Three Approved Indications: A Tumor-Agnostic Approach to a Single Molecular Target

    Bizengri is now approved across three cancer types defined by the same molecular alteration:

    IndicationApproval dateSetting
    NRG1+ non-small cell lung cancerDecember 4, 2024After prior systemic therapy
    NRG1+ pancreatic adenocarcinomaDecember 4, 2024After prior systemic therapy
    NRG1+ cholangiocarcinoma (biliary tract)May 8, 2026After prior systemic therapy

    This approval strategy, using one molecular biomarker to justify approval across histologically distinct cancers, is the definition of a tumor-agnostic or biomarker-driven approach. The NRG1 fusion is the target, and the tissue of origin is secondary. This pattern follows the FDA’s broader shift toward molecular rather than anatomical cancer classifications, exemplified by earlier tumor-agnostic approvals such as pembrolizumab for MSI-H/dMMR tumors and larotrectinib for TRK fusion-positive cancers.

    The CNPV connection is also relevant here. For related coverage of how the CNPV program has been used to accelerate approvals for other conditions in 2026, see our post on the FDA’s fast-tracking of psychedelic drug programs for mental illness and our post on the first gene therapy for genetic deafness, the first gene therapy approved under CNPV.

    The eNRGy Trial Cholangiocarcinoma Cohort: What the Evidence Shows

    Trial design

    eNRGy (NCT02912949) is a Phase 1/2, open-label, registrational, multicenter basket trial evaluating zenocutuzumab across multiple solid tumor types harboring NRG1 fusions. The basket design is appropriate for rare molecular alterations that appear across multiple histologies: rather than running a separate trial for each tumor type, a single trial enrolls all patients with the molecular target regardless of where the cancer originated.

    The cholangiocarcinoma cohort enrolled patients with advanced, unresectable or metastatic cholangiocarcinoma harboring NRG1 gene fusions whose disease had progressed on or after prior systemic therapy. NRG1 fusion status was required to be confirmed by molecular testing.

    Efficacy results

    OutcomeCholangiocarcinoma cohort (n=19 evaluable)
    Overall response rate (ORR)36.8% (95% CI 16.3 to 61.6%)
    Number of confirmed responders7 of 19 patients
    Duration of responseRange: 2.8 to 12.9 months
    Assessment methodRECIST v1.1, blinded independent central review

    Source: FDA approval, May 8, 2026. Presented at AACR/NCI/EORTC Conference on Molecular Targets and Cancer Therapeutics, October 2025, Boston.

    Interpreting the results in context

    A 36.8% ORR in a 19-patient cohort must be understood within the context of several important facts.

    The denominator is tiny because the disease is rare. NRG1 fusion-positive cholangiocarcinoma affects only an estimated few hundred Americans per year. Running a trial large enough to power a survival analysis in this population would take many years and deny patients in the interim a therapy that is producing clinically meaningful responses. The FDA’s standard for approvals in ultra-rare molecularly defined cancers appropriately accounts for this constraint.

    The comparator context is chemotherapy. Historically, patients with advanced cholangiocarcinoma whose disease has progressed after first-line therapy have had very limited options with response rates in the range of 5 to 15% to second-line chemotherapy. A 36.8% ORR against this background represents a meaningfully differentiated result.

    The basket trial precedent is established. The NSCLC and pancreatic cancer approvals from December 2024 were based on the same eNRGy trial using the same basket design. In the NSCLC cohort (n=30), the ORR was 33% with a median duration of response of 7.4 months. In the pancreatic cohort (n=30), the ORR was 40% with a median duration of 5.9 months. The cholangiocarcinoma ORR of 36.8% is consistent with the pattern observed across tumor types in this molecular subset, further supporting the NRG1 fusion as a clinically actionable driver across histologies.

    Why small basket trial cohorts are acceptable for molecular-rare cancers The FDA’s framework for tumor-agnostic and rare molecular alteration approvals recognizes that conventional large randomized trial design is not feasible when the target population may number in the hundreds rather than thousands. The standard applied is whether the evidence is clinically meaningful and sufficiently robust to support a reliable benefit-risk assessment. For Bizengri in NRG1+ cholangiocarcinoma, the 36.8% ORR from a prospectively conducted, centrally reviewed cohort in a registrational basket trial, in a disease with no approved targeted therapy and historically poor response to chemotherapy, meets this standard. The approval was also supported by the mechanistic coherence of responses across three tumor types in the same trial, which substantially strengthens the interpretation of the cholangiocarcinoma cohort data.

    Safety

    The safety profile of zenocutuzumab in the cholangiocarcinoma cohort was consistent with its established profile across other NRG1+ tumor types in eNRGy.

    Common adverse reactions (consistent with class and mechanism): infusion-related reactions, fatigue, nausea, diarrhea, musculoskeletal pain, decreased appetite.

    Serious adverse reactions: Serious infusion-related reactions can occur and require premedication per the prescribing information and monitoring during each infusion.

    Left ventricular dysfunction: HER2-targeting antibodies carry a class risk of cardiotoxicity including left ventricular dysfunction and decreased ejection fraction. Monitor cardiac function per prescribing information. Patients with pre-existing significant cardiac disease require careful evaluation before initiating treatment.

    Embryo-fetal toxicity: Zenocutuzumab targets HER2 and HER3, growth factor receptors that play roles in fetal development. Females of reproductive potential should use effective contraception during treatment and for 7 months after the last dose. Males should use effective contraception during treatment and for 4 months after the last dose.

    For the complete adverse event profile and dose modification guidance, the full prescribing information should be reviewed before initiating treatment.

    Dosing and Administration

    ParameterDetails
    Dose750 mg intravenous infusion
    ScheduleEvery 2 weeks (14-day cycle)
    PremedicationPer prescribing information before each infusion
    SettingHealthcare facility capable of managing infusion reactions
    Continue untilDisease progression or unacceptable toxicity

    The CNPV Connection: How the Approval Was Expedited

    The Bizengri cholangiocarcinoma approval used the Commissioner’s National Priority Voucher (CNPV) program for the first time in an oncology/rare cancer setting. The CNPV was awarded to Partner Therapeutics on May 6, 2026, and the FDA approved the cholangiocarcinoma indication just two days later on May 8, 2026. The CNPV compressed the standard review timeline by applying priority review resources immediately, accelerating access to a therapy for a population with urgent unmet need.

    The CNPV’s use in NRG1+ cholangiocarcinoma reflects the FDA’s recognition that rare molecular subsets of aggressive cancers can represent conditions of national health significance warranting the same acceleration tools applied to other priority public health areas.

    What This Means for Patients and Clinicians

    For patients with cholangiocarcinoma

    If you have been diagnosed with cholangiocarcinoma and your tumor has not yet been tested for NRG1 fusions, this approval is a reason to discuss molecular testing with your oncologist. NRG1 fusions are rare in this cancer type, but they are actionable: if present, Bizengri is now an FDA-authorized option after disease progression on prior systemic therapy.

    Comprehensive molecular testing platforms that include RNA-based fusion detection are available at major academic centers and through commercial laboratory services. Testing requirements and ordering should be discussed with your oncologist.

    For oncologists managing cholangiocarcinoma

    The approval of zenocutuzumab completes a third actionable molecular subset for cholangiocarcinoma (alongside FGFR2 fusions, IDH1 mutations, and HER2 amplification/overexpression). Comprehensive molecular profiling including RNA-based sequencing at the time of diagnosis or upon progression is increasingly essential for identifying all available targeted options.

    For patients whose NRG1 fusion status has not been determined, RNA sequencing should be requested specifically if standard next-generation sequencing panels are DNA-only. NRG1 fusions may be underdetected in DNA-based panels due to their intronic structure.

    Clinical trial opportunities

    Additional clinical development of zenocutuzumab in earlier lines and in combination regimens is ongoing. ClinicalTrials.gov and ClinicalTrials.gov for zenocutuzumab broadly list currently enrolling studies for patients interested in investigational options.

    The Cholangiocarcinoma Foundation is the leading U.S. patient advocacy organization for bile duct cancer and maintains current information on approved therapies, clinical trials, and specialist referral resources. The American Liver Foundation and NCI cholangiocarcinoma information provide clinical and research overviews.

    For related HED coverage of other molecularly targeted oncology approvals, see our post on Lifyorli (relacorilant) and the novel cortisol-resistance mechanism in platinum-resistant ovarian cancer and our post on Datroway (datopotamab deruxtecan) achieving its third approved indication in triple-negative breast cancer.

    Sources

    FDA approval announcement: FDA approves zenocutuzumab-zbco for advanced, unresectable or metastatic cholangiocarcinoma. FDA.gov. May 8, 2026.

    Partner Therapeutics press release: Partner Therapeutics Announces FDA Approval of BIZENGRI (zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner’s National Priority Voucher. partnertx.com. May 11, 2026.

    CNPV award press release: Partner Therapeutics Announces Receipt of FDA Commissioner’s National Priority Voucher for Bizengri in NRG1 Fusion-Positive Cholangiocarcinoma. drugs.com. May 6, 2026.

    CancerNetwork clinical coverage: FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy. cancernetwork.com. May 2026.

    Targeted Oncology clinical coverage: FDA Approves Zenocutuzumab for NRG1 Fusion-Positive Cholangiocarcinoma. targetedonc.com. May 2026.

    PharmExec approval coverage: FDA Approves Bizengri for Adults with NRG1 Fusion-Positive Cholangiocarcinoma. pharmexec.com. May 2026.

    ONS clinical summary: FDA Approves Zenocutuzumab-Zbco for Advanced, Unresectable, or Metastatic Cholangiocarcinoma. ons.org. May 2026.

    eNRGy trial registration: NCT02912949. ClinicalTrials.gov.

    Bizengri original FDA approval (NSCLC/pancreas, December 2024): FDA approves zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma. FDA.gov. December 2024.

    AACR/NCI/EORTC 2025 CCA presentation: Schram AM, Cleary JM, Arnold D, et al. Zenocutuzumab efficacy and safety in advanced NRG1+ cholangiocarcinoma: analysis from the phase 2 eNRGy trial. Presented at AACR/NCI/EORTC Conference, October 2025, Boston.

    NRG1 and HER signaling review: NRG1-HER3 signaling in cancer. PMC7297124.

    Zenocutuzumab mechanism: Bispecific antibodies targeting HER2/HER3. PMC9891442.

    NRG1 gene: NRG1 gene. NCBI.

    Cholangiocarcinoma overview: Bile Duct Cancer. American Cancer Society.

    FDA tumor-agnostic drug approvals: Tumor Agnostic Approvals. FDA.gov.

    CNPV program: Commissioner’s National Priority Voucher. FDA.gov.

    Breakthrough Therapy Designation: Breakthrough Therapy. FDA.gov.

    Orphan Drug Designation: Designating an Orphan Product. FDA.gov.

    Patient resources: Cholangiocarcinoma Foundation | American Liver Foundation: Bile Duct Cancer | NCI Cholangiocarcinoma | ClinicalTrials.gov: zenocutuzumab

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Treatment decisions for cholangiocarcinoma, including molecular testing decisions and therapy selection, should be made in consultation with a qualified oncologist experienced in biliary tract malignancies. Molecular testing for NRG1 fusions requires appropriate RNA-based sequencing; consult your oncologist about which testing platform is appropriate.
  • The Only Approved High-Efficacy MS Treatment for Children Is Now Ocrevus. Here Is What the OPERETTA 2 Trial Data Shows.

    The Only Approved High-Efficacy MS Treatment for Children Is Now Ocrevus. Here Is What the OPERETTA 2 Trial Data Shows.

    📌 The essentials On May 8, 2026, the FDA approved Ocrevus (ocrelizumab, Genentech) for the treatment of relapsing-remitting multiple sclerosis (RRMS) in pediatric patients aged 10 years and older who weigh at least 25 kg (approximately 55 pounds). This is Ocrevus’s first pediatric indication, expanding its label beyond adults. Ocrevus becomes only the second FDA-approved disease-modifying therapy for pediatric RRMS, after fingolimod (Gilenya, Novartis), and the first approved high-efficacy anti-CD20 therapy for this population. The clinical basis: Phase 3 OPERETTA 2 trial (NCT05123703), 187 pediatric patients aged 10 to 17 years with RRMS, randomized double-blind comparison of ocrelizumab versus fingolimod. Primary endpoint: ocrelizumab was non-inferior to fingolimod in reducing annualized relapse rate. MRI superiority: 48% reduction in new or enlarging T2 lesions (p=0.001) and 87% reduction in gadolinium-enhancing T1 lesions (p=0.001) versus fingolimod. Safety: no adverse events led to treatment withdrawal in the ocrelizumab arm. How it is given: 600 mg intravenous infusion every 24 weeks (same dose and schedule as adults). Weight minimum: the drug is not known to be safe or effective in children under 10 years of age or weighing less than 25 kg.

    Multiple sclerosis in children and adolescents is a different clinical scenario than most people picture when they think of MS. Pediatric-onset MS (POMS) represents approximately 3 to 5% of all MS cases globally, with an estimated 5,000 to 10,000 children and adolescents affected in the United States. The condition is not mild: children with POMS typically have higher relapse rates than adults, more rapid accumulation of new brain lesions on MRI, and a relapsing disease course in the vast majority of cases. What they have historically had is very few approved treatment options.

    Until May 8, 2026, fingolimod (Gilenya) was the only FDA-approved disease-modifying therapy for pediatric RRMS, a status it has held since its pediatric approval in 2018. Every other MS treatment used in children and adolescents was prescribed off-label, without the clinical trial evidence base that formal approval requires.

    That changed when the FDA approved Ocrevus (ocrelizumab) for RRMS in patients aged 10 and older, based on the Phase 3 OPERETTA 2 trial. For the first time, a high-efficacy anti-CD20 B-cell depleting therapy is formally available for pediatric patients who have not responded adequately to first-line agents or whose disease activity warrants a more aggressive approach from the start.

    What Pediatric-Onset Multiple Sclerosis Is and Why Treatment Is Urgent

    Pediatric-onset MS is defined as MS with symptom onset before age 18. Children and adolescents with POMS experience the same types of episodes as adults, including optic neuritis, limb weakness, sensory disturbance, brainstem and cerebellar dysfunction, and cognitive slowing. But several features distinguish POMS from typical adult-onset disease.

    Higher initial disease activity: Children with POMS typically have higher relapse rates than adult patients early in the disease course. Brain MRI at diagnosis often shows extensive T2 lesion burden. The inflammatory activity is often vigorous, reflecting the heightened immune responsiveness of the developing immune system.

    Predominantly relapsing course: Nearly all pediatric MS cases are relapsing-remitting, not progressive, at onset. This is both a prognostic advantage (the disease course is more amenable to disease modification) and a treatment priority (relapses in developing brains carry distinct risks for cognitive and neurological development that are not fully quantified in adults).

    Cognitive burden: Cognitive impairment is documented in a substantial proportion of children with MS, affecting processing speed, attention, memory, and executive function. Because POMS occurs during a critical period of brain development and education, the impact of unchecked disease activity on long-term cognitive trajectory is a distinct and serious concern.

    Long disease duration ahead: A child diagnosed at age 12 faces potentially decades of living with MS before the disease is biologically comparable to someone diagnosed at 50. The cumulative burden of every avoided relapse, every suppressed lesion, and every year of preserved neurological function compounds over that longer horizon.

    Why fingolimod was the only approved option for so long, and what its limitations are Fingolimod (Gilenya) was the first FDA-approved MS therapy for pediatric patients, receiving its pediatric RRMS approval in May 2018 based on the Phase 3 PARADIGMS trial. It works by sequestering lymphocytes in lymph nodes, preventing them from entering the central nervous system and causing inflammation. It is effective and its oral administration is an advantage for younger patients. But it carries significant safety concerns: a first-dose cardiac monitoring requirement (due to the risk of bradycardia and heart block), risk of serious infections including PML and cryptococcal meningitis, varicella zoster reactivation, and ophthalmologic monitoring requirements for macular edema. In a pediatric population, these monitoring requirements represent a real burden on families, schools, and clinical teams. Until OPERETTA 2, the absence of a high-efficacy alternative with a clinically distinct mechanism and monitoring profile left neurologists and families with limited flexibility.

    How Ocrelizumab Works and Why B-Cell Depletion Matters in MS

    Ocrelizumab is a humanized anti-CD20 monoclonal antibody. CD20 is a surface protein expressed on B cells throughout most of their development, from pre-B cells through mature B cells, but not on plasma cells or hematopoietic stem cells. When ocrelizumab binds CD20, it triggers B-cell depletion through three mechanisms: antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis induction.

    The role of B cells in MS pathogenesis has been substantially clarified in the decade since ocrelizumab’s original approval. B cells contribute to MS inflammation not just as antibody-producing cells but as antigen-presenting cells that activate CD4+ and CD8+ T cells, as producers of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-12, and as modulators of the inflammatory microenvironment within CNS lesions. Depleting B cells interrupts these multiple contributions to disease activity, producing the robust efficacy on both relapse rates and MRI lesion accumulation that has made ocrelizumab one of the most effective MS therapies in adult practice.

    In the pediatric setting, ocrelizumab’s mechanism offers specific theoretical advantages: because POMS is characterized by highly active inflammatory disease, the near-complete B-cell depletion produced by ocrelizumab (blood B-cell counts typically fall to undetectable levels within 2 weeks of the first infusion and remain suppressed for the 24-week dosing interval) may be particularly well-matched to the disease biology. The OPERETTA 2 data tests this hypothesis directly.

    The OPERETTA 2 Trial: Full Results

    Design

    OPERETTA 2 (NCT05123703) was a randomized, double-blind, double-dummy, multicenter Phase 3 noninferiority trial. The double-dummy design means that all patients received both an IV infusion and an oral daily capsule, with one being the active drug and the other a matching placebo, ensuring neither patients nor investigators knew which treatment was assigned.

    The trial enrolled 187 pediatric patients aged 10 to 17 years with RRMS, randomized 1:1 to:

    • Ocrelizumab 600 mg intravenous infusion every 24 weeks, plus oral placebo daily (n approximately 94)
    • Fingolimod 0.5 mg oral capsule daily, plus intravenous placebo infusion every 24 weeks (n approximately 93)

    OPERETTA 2 was designed to demonstrate non-inferiority of ocrelizumab to fingolimod. The dose of ocrelizumab (600 mg every 24 weeks) is the same as the approved adult dose, a decision supported by pharmacokinetic and pharmacodynamic data from the companion OPERETTA 1 study that characterized ocrelizumab’s PK profile in the pediatric age range and confirmed that the adult dose produces comparable drug exposure in children aged 10 and older weighing at least 25 kg.

    Primary endpoint

    OutcomeOcrelizumabFingolimodComparison
    Annualized relapse rate (ARR)Significantly reducedReferenceNon-inferior (rate ratio 0.52; 95% CI 0.19 to 1.33)
    Primary non-inferiority endpointMetReferencep-value consistent with non-inferiority

    MRI endpoints (superiority)

    MRI OutcomeOcrelizumabFingolimodComparison
    New or enlarging T2 hyperintense lesions per MRI scan3.7787.235Relative reduction 47.8%; p=0.001
    Mean T1 gadolinium-enhancing lesions at week 120.0310.243Relative reduction 87.2%; p=0.001

    Source: OPERETTA 2 trial, NCT05123703. Genentech/FDA press release, May 8, 2026. Presented at AAN 2026 and published in advance of peer-reviewed journal publication.

    Interpreting the results

    The primary non-inferiority finding means ocrelizumab reduced annualized relapse rates in a manner that was statistically no worse than fingolimod, the current standard of care for this population. The 95% confidence interval for the rate ratio (0.19 to 1.33) is wide, reflecting the challenge of powering pediatric trials with small populations, but the point estimate (0.52) suggests that relapses were approximately 48% less frequent with ocrelizumab, a numerically superior result that did not reach formal superiority on the relapse endpoint.

    The MRI superiority findings are the more clinically discriminating results. A 48% reduction in new or enlarging T2 lesions and an 87% reduction in gadolinium-enhancing lesions versus fingolimod at week 12 are substantial advantages on the imaging markers that most directly reflect ongoing inflammatory disease activity. These MRI findings align with what was observed in adult comparisons of ocrelizumab versus other MS therapies: the anti-CD20 mechanism produces particularly deep suppression of new lesion formation, which correlates with long-term disability protection in adult studies.

    Safety in OPERETTA 2

    The safety profile of ocrelizumab in pediatric patients in OPERETTA 2 was consistent with its well-established nine-year adult safety record. The most commonly reported adverse events were infusion reactions, infections, and decreases in immunoglobulin levels, identical in type to what is documented in adult trials.

    Notably, no adverse events led to treatment withdrawal in the ocrelizumab arm during the double-blind period. This finding on discontinuation due to adverse events is clinically meaningful given that tolerability-driven discontinuation is one of the practical challenges of fingolimod’s first-dose cardiac monitoring requirement and ongoing ophthalmologic surveillance.

    MSBase Registry real-world data presented at the 2026 CMSC Annual Meeting further supports the OPERETTA 2 findings: an analysis of pediatric-onset MS patients in the registry showed that ocrelizumab maintained similar effectiveness and safety in pediatric-onset disease compared to young-adult onset disease, providing external validation from clinical practice in countries where ocrelizumab has been used off-label or under compassionate access in pediatric patients.

    Ocrevus’s Full Approved Indication Picture After May 2026

    With the pediatric RRMS approval, Ocrevus now carries the following FDA-approved indications:

    IndicationPopulationApproval date
    Relapsing forms of MS (CIS, RRMS, active SPMS)AdultsMarch 2017
    Primary progressive MSAdultsMarch 2017
    RRMSPediatric patients aged 10 years and older weighing at least 25 kgMay 8, 2026

    Ocrevus also has a subcutaneous formulation, Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq), approved in September 2024 for adults, which delivers the same dose subcutaneously in 10 minutes rather than the 3.5-hour intravenous infusion. The subcutaneous formulation is currently approved for adults only; the pediatric indication uses the intravenous formulation.

    Safety Considerations for the Pediatric Population

    The safety profile of ocrelizumab is well-established from more than nine years of adult use and now confirmed in OPERETTA 2 for the pediatric setting. Key considerations for parents and pediatric neurologists:

    Infusion reactions: The most common adverse event during ocrelizumab treatment is infusion-related reactions occurring during or within 24 hours of infusion. Pre-medication with corticosteroids, antihistamines, and analgesics is administered before each infusion per protocol. These reactions are typically mild to moderate and manageable.

    Infections: Because B-cell depletion reduces one component of humoral immunity, patients on ocrelizumab are at modestly increased risk of respiratory infections, particularly upper respiratory tract infections. Serious infections occurred at low rates in both adult and pediatric trials. Opportunistic infections including PML (caused by JC virus) have been reported rarely in adult patients, primarily in those with additional immunocompromising factors.

    Decreasing immunoglobulins: Long-term B-cell depletion leads to gradual decline in IgG and IgM levels over years of treatment. Monitor immunoglobulin levels periodically. Significant hypogammaglobulinemia may require dose adjustment or management in some patients.

    Vaccinations: Live vaccines should not be administered during treatment or until B cells have reconstituted after stopping treatment. All recommended immunizations should be completed before initiating Ocrevus. This is particularly important in the pediatric setting where routine childhood vaccination schedules need to be coordinated with treatment initiation.

    PML risk: Ocrevus carries a boxed warning for progressive multifocal leukoencephalopathy (PML), though the absolute risk appears substantially lower than with natalizumab (Tysabri). No cases of PML were reported in OPERETTA 2.

    Dosing and Administration for Pediatric Patients

    ParameterDetails
    Approved dose (ages 10 and older, weight at least 25 kg)600 mg IV every 24 weeks
    First doseTwo 300 mg infusions given 2 weeks apart
    Subsequent dosesSingle 600 mg infusion every 24 weeks
    Pre-medication requiredMethylprednisolone (or equivalent corticosteroid) IV, antihistamine, and optional antipyretic before each infusion
    Infusion duration (600 mg)Approximately 3.5 hours
    SettingHealthcare facility with emergency equipment and resuscitation capability available
    Weight requirementAt least 25 kg (approximately 55 lbs)
    Age lower limit10 years and older
    Not forChildren under 10 years of age or weighing less than 25 kg

    What This Approval Means for Families and Pediatric Neurologists

    For families of children with RRMS

    For the first time, a family whose child has RRMS has a choice between two FDA-approved treatment options rather than only one. Ocrevus, administered every six months as an intravenous infusion, offers a different monitoring profile, mechanism of action, and efficacy signal than daily oral fingolimod.

    Practical considerations for families when discussing this option with your child’s neurologist:

    • Ocrevus is infused twice a year. Fingolimod is taken daily. For some families, twice-yearly clinic visits for infusion are more manageable than ensuring daily adherence; for others, the infusion schedule is a barrier.
    • The first-dose cardiac monitoring requirement with fingolimod is not required with Ocrevus.
    • The ophthalmologic monitoring required with fingolimod is not required with Ocrevus.
    • The 87% reduction in gadolinium-enhancing lesions at week 12 versus fingolimod in OPERETTA 2 indicates a measurably deeper suppression of active inflammation with Ocrevus in the pediatric trial.
    • All immunizations should be current and any live vaccines completed before starting Ocrevus. This timing requires planning with your child’s pediatrician and neurologist.

    For pediatric neurologists

    OPERETTA 2 provides the first randomized head-to-head controlled evidence comparing a high-efficacy anti-CD20 therapy to fingolimod in pediatric RRMS. The non-inferiority on ARR combined with superiority on both MRI endpoints justifies positioning ocrelizumab as a strong option for treatment-naive patients with active disease, not just as a step-up therapy after fingolimod failure.

    The absence of treatment withdrawal due to adverse events in the ocrelizumab arm is a meaningful tolerability signal in a population where treatment persistence over years and decades is the goal. Monitoring requirements for ocrelizumab are primarily infusion reaction surveillance, immunoglobulin levels, and standard infection monitoring, rather than the cardiac and ophthalmologic monitoring that fingolimod requires.

    The American Academy of Neurology and the International Pediatric MS Study Group will be updating their guidance frameworks in response to this approval. The National MS Society’s healthcare providers section provides updated clinical resources.

    For families: the National MS Society and Can Do MS both maintain dedicated pediatric MS resources. The International Pediatric MS Study Group connects families with specialized clinical expertise.

    For related HED coverage of other neurological condition approvals and anti-CD20 therapy advances in 2026, see our post on Fasenra (benralizumab) approved for hypereosinophilic syndrome as another example of a biologic agent expanding from adult to pediatric and rare disease settings, and our post on VYVGART and the first approval covering all forms of myasthenia gravis.

    Sources

    FDA approval announcement: FDA approves ocrelizumab for relapsing-remitting multiple sclerosis in pediatric patients 10 years of age and older. FDA.gov. May 8, 2026.

    Genentech press release: FDA Approves Ocrevus for Relapsing-Remitting Multiple Sclerosis in Pediatric Patients 10 Years of Age and Older. gene.com. May 8, 2026.

    Drugs.com approval news: FDA Approves Ocrevus for Relapsing-Remitting Multiple Sclerosis In Pediatric Patients 10 Years of Age and Older. drugs.com. May 2026.

    NeurologyLive clinical summary: FDA Approves Ocrelizumab for Pediatric Patients With Relapsing-Remitting Multiple Sclerosis. neurologylive.com. May 2026.

    Neurology Advisor detailed coverage: Ocrevus Approved for Pediatric Relapsing-Remitting Multiple Sclerosis. neurologyadvisor.com. May 2026.

    Pharmacy Times clinical review: FDA Approves Ocrelizumab for Pediatric Relapsing-Remitting Multiple Sclerosis. pharmacytimes.com. May 2026.

    Medscape coverage: FDA Approves Ocrelizumab for Pediatric Relapsing MS. medscape.com. May 2026.

    MS News Today coverage: In ‘landmark’ approval, FDA OKs Ocrevus for kids 10 and older with RRMS. multiplesclerosisnewstoday.com. May 2026.

    CMSC 2026 real-world data: CMSC 2026: Real-World Analysis Supports Ocrelizumab Use in Pediatric-Onset Multiple Sclerosis. neurologylive.com. May 2026.

    Practical Neurology: FDA Approves Ocrevus for Pediatric Relapsing-Remitting MS. practicalneurology.com. May 2026.

    OPERETTA 2 trial registration: NCT05123703. ClinicalTrials.gov.

    Ocrevus original FDA approval: FDA approves ocrelizumab for multiple sclerosis. FDA.gov. March 2017.

    Fingolimod pediatric approval: FDA approves fingolimod for pediatric patients with multiple sclerosis. FDA.gov. 2018.

    Ocrevus prescribing information: OCREVUS (ocrelizumab) Prescribing Information. Genentech. 2026.

    Ocrelizumab mechanism review: CD20-directed B-cell depleting therapies in MS. PMC6369883.

    Pediatric MS StatPearls: Pediatric Multiple Sclerosis. StatPearls. NCBI.

    Pediatric MS cognitive effects: Cognitive Impairment in Pediatric Multiple Sclerosis. PMC7897219.

    ADCC mechanism: Antibody-Dependent Cell-Mediated Cytotoxicity. StatPearls. NCBI.

    National MS Society pediatric resources: Pediatric MS. nationalmssociety.org.

    Patient resources: National MS Society: Pediatric MS | International Pediatric MS Study Group | Can Do MS | American Academy of Neurology

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about MS treatment, including the choice of disease-modifying therapy for pediatric patients, should be made in close consultation with a pediatric neurologist or MS specialist experienced in pediatric-onset multiple sclerosis.
  • BPDCN Has Been Diagnosed in Hundreds of Americans Each Year With Almost No Approved Treatment Options. Decnupaz Just Changed That.

    BPDCN Has Been Diagnosed in Hundreds of Americans Each Year With Almost No Approved Treatment Options. Decnupaz Just Changed That.

    📌 The essentials On May 27, 2026, the FDA approved Decnupaz (pivekimab sunirine-pvzy, AbbVie) for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an ultra-rare and aggressive hematologic malignancy. This is the second FDA-approved therapy for BPDCN and the first CD123-directed antibody-drug conjugate to receive FDA approval. Decnupaz is a first-in-class agent approved for both treatment-naive and relapsed or refractory BPDCN, making it applicable across all lines of therapy. Regulatory designations: Breakthrough Therapy Designation, Orphan Drug Designation, Priority Review. The clinical basis: Phase 1/2 CADENZA trial (NCT03386513), 84 adult patients (33 treatment-naive, 51 relapsed or refractory), open-label, single-arm. Primary endpoint: complete remission or clinical complete remission (CR/CRc) rate. Treatment-naive: 69.7% CR/CRc rate (95% CI 51.3 to 84.4%) at 21.5 months median follow-up; median duration of CR/CRc 9.7 months. Relapsed or refractory: 15.7% CR/CRc rate (95% CI 7.0 to 28.6%) at 24.1 months median follow-up; median duration of CR/CRc 9.2 months. Bridging to transplant: 39.4% of treatment-naive patients proceeded to post-study stem cell transplantation, a critical finding in a disease where bridging to transplant is a primary treatment goal. Boxed warning: hepatotoxicity including hepatic veno-occlusive disease (VOD). Dosing: 0.045 mg/kg intravenously over 15 to 30 minutes once every 3 weeks (21-day cycle).

    There are diseases that most physicians will never see in a career, not because they are mild or easily ignored, but because they are so rare that the entire diagnosed population in the United States numbers in the hundreds per year. Blastic plasmacytoid dendritic cell neoplasm is one of them.

    BPDCN is an aggressive blood cancer that arises from plasmacytoid dendritic cell precursors, presenting most often in older adults as skin lesions combined with bone marrow involvement and sometimes rapid spread to other organs. It carries a historically poor prognosis: median overall survival in historical series without transplantation has ranged from 8 to 14 months. The only previously approved targeted therapy for BPDCN was tagraxofusp (Elzonris), a CD123-directed cytotoxin approved in 2018, leaving a significant gap particularly in the relapsed and refractory setting.

    On May 27, 2026, the FDA approved Decnupaz (pivekimab sunirine-pvzy), a first-in-class CD123-directed antibody-drug conjugate developed by AbbVie (originally by ImmunoGen before AbbVie’s 2024 acquisition), for adult patients with BPDCN in both treatment-naive and relapsed or refractory settings. The approval is based on the CADENZA trial, which enrolled 84 patients across a disease population so rare that the trial itself represents one of the largest BPDCN clinical datasets ever assembled.

    What BPDCN Is and Why It Is So Difficult to Treat

    The cell of origin

    BPDCN arises from the malignant transformation of plasmacytoid dendritic cell precursors, a rare subset of immune cells that normally circulate in blood and reside in lymphoid tissues. Plasmacytoid dendritic cells (pDCs) are specialized innate immune cells responsible primarily for producing large quantities of type I interferons in response to viral infection. In BPDCN, these precursors undergo malignant transformation and proliferate in a manner that is neither classically leukemic nor typically lymphomatous but shares features of both.

    The disease was historically confusing to classify, previously known as agranular CD4+ CD56+ hematodermic neoplasm or blastic NK-cell lymphoma before its origin from pDC precursors was established. Its current classification as a distinct entity in the World Health Organization classification of hematologic malignancies reflects this now-understood biology.

    Clinical presentation and typical course

    BPDCN presents most commonly in adults over 60, with a strong male predominance (approximately 3:1 male-to-female ratio). The hallmark presentation is cutaneous involvement: bruise-like or reddish-brown skin lesions, nodules, or widespread plaques that can be widespread on the body surface. Bone marrow involvement is present in most patients at diagnosis, and peripheral blood involvement (leukemic phase) develops in many. The liver, spleen, and lymph nodes are other common sites.

    An important clinical complexity is that BPDCN frequently presents concurrently with or evolves from other hematologic malignancies, including chronic myelomonocytic leukemia (CMML), myelodysplastic syndromes (MDS), and other myeloid neoplasms. In the CADENZA trial, 11 of the 33 treatment-naive patients had prior or concurrent cancer diagnoses in addition to BPDCN, reflecting real-world disease complexity.

    Disease progression is typically rapid. Without effective treatment, the course from initial presentation to systemic organ involvement can be weeks to months.

    The CD123 target: why BPDCN is uniquely susceptible CD123, the interleukin-3 receptor alpha chain (IL-3Rα), is a cell surface protein that is highly and consistently overexpressed on BPDCN cells across virtually all patients with the disease. IL-3 signaling through CD123 promotes the survival and proliferation of pDC precursors, and in BPDCN, this overexpression is not incidental but functionally important to the malignant cell’s biology. The near-universal CD123 overexpression in BPDCN makes it one of the best-matched malignancies for CD123-targeted therapy of any cancer type. Both approved BPDCN therapies, tagraxofusp and now Decnupaz, exploit this target. The CADENZA trial required CD123 positivity confirmed by flow cytometry or immunohistochemistry for enrollment, ensuring that all patients in the trial had the target expression pattern needed for the drug to work.

    How Decnupaz Works: A First-in-Class ADC Mechanism

    Decnupaz (pivekimab sunirine-pvzy) is an antibody-drug conjugate (ADC) with three distinct components:

    The antibody: A high-affinity anti-CD123 monoclonal antibody that binds specifically to CD123 expressed on BPDCN cells. When the antibody binds CD123, the drug-receptor complex is internalized into the cell.

    The linker: A cleavable linker that connects the antibody to the payload. After internalization, the linker is cleaved by intracellular enzymes, releasing the active payload inside the cancer cell.

    The payload: An indolinobenzodiazepine pseudodimer (IGN), a potent DNA alkylating agent that alkylates DNA and causes single-strand DNA breaks without crosslinking. The mechanism of single-strand DNA damage without crosslinking is pharmacologically distinct from conventional alkylating chemotherapy, which typically crosslinks DNA. This distinction is designed to produce cytotoxicity in the targeted cancer cells while limiting some of the toxicity patterns associated with conventional alkylators.

    This mechanism is what makes pivekimab sunirine a first-in-class agent: no previously approved drug uses an indolinobenzodiazepine pseudodimer payload in an ADC. The combination of the CD123-targeting antibody with this specific payload represents a novel mechanistic approach to BPDCN treatment.

    Decnupaz differs from tagraxofusp in mechanism: tagraxofusp is a CD123-directed cytotoxin that consists of IL-3 fused to truncated diphtheria toxin, producing cell killing through a protein synthesis inhibition mechanism. Decnupaz delivers a DNA-damaging payload via ADC technology, offering a different mechanism of action for patients who have failed or cannot receive tagraxofusp.

    The CADENZA Trial: Full Results

    Design

    CADENZA (NCT03386513) is a multicenter, open-label, single-arm Phase 1/2 trial that enrolled adults aged 18 and older with BPDCN with CD123 positivity confirmed by flow cytometry or immunohistochemistry and no evidence of active central nervous system disease. Two distinct cohorts were enrolled:

    • Treatment-naive BPDCN (n=33): patients with no prior BPDCN-directed systemic therapy
    • Relapsed or refractory BPDCN (n=51): patients who had received at least one prior line of therapy

    The primary efficacy endpoint was the rate of complete remission (CR) or clinical complete remission (CRc). CR was defined as complete resolution of all BPDCN manifestations with full hematologic recovery. CRc was defined as complete resolution of all BPDCN manifestations with incomplete hematologic recovery (analogous to the CRi designation used in AML).

    Primary endpoint results: treatment-naive cohort

    OutcomeTreatment-naive BPDCN (n=33)
    CR/CRc rate69.7% (95% CI 51.3 to 84.4%)
    Number of patients achieving CR/CRc23 of 33
    Median follow-up21.5 months
    Median duration of CR/CRc9.7 months (95% CI 2.9 to not estimable)
    Patients proceeding to post-study stem cell transplantation39.4% (13 of 33)
    Median overall survival (all treatment-naive, n=33)16.6 months (95% CI 11.4 to not reached)
    12-month OS rate64% (95% CI 44.9 to 77.5%)
    18-month OS rate44% (95% CI 26.7 to 60.3%)

    Primary endpoint results: relapsed or refractory cohort

    OutcomeRelapsed or refractory BPDCN (n=51)
    CR/CRc rate15.7% (95% CI 7.0 to 28.6%)
    Number of patients achieving CR/CRc8 of 51
    Median follow-up24.1 months
    Median duration of CR/CRc9.2 months (range 2.7 to 27.6 plus months)

    Source: CADENZA trial, NCT03386513. FDA approval notice, May 27, 2026. OncLive and Targeted Oncology clinical coverage.

    The transplant bridge finding: the most clinically important secondary result

    In the treatment-naive cohort, 39.4% of patients (13 of 33) proceeded to post-study stem cell transplantation after achieving response with Decnupaz. This finding is critically important in BPDCN because allogeneic stem cell transplantation is the only treatment approach associated with potential long-term cure in this disease. The primary role of induction therapy in BPDCN is often conceptualized as achieving a remission deep enough to bridge the patient to transplant while they remain in adequate condition to tolerate it.

    A CR/CRc rate of 69.7% in treatment-naive patients, with 39.4% successfully bridging to transplant, represents a meaningful clinical achievement for a disease where achieving remission adequate for transplant eligibility has historically been extremely difficult.

    The durability finding in the relapsed or refractory cohort also deserves specific attention: the median CR/CRc duration of 9.2 months in heavily pretreated patients, in a setting where overall response rates are low (15.7%), means that the patients who do respond achieve durable remissions comparable in length to those seen in the treatment-naive setting. This suggests that the drug’s mechanism produces meaningful responses when it works, across disease stages.

    Why single-arm trial data is accepted for ultra-rare cancer approvals BPDCN affects an estimated 500 to 1,000 patients per year in the United States. Running a randomized controlled trial with a placebo or active comparator arm in a disease this rare would take many years of enrollment, during which patients in the control arm would face disease progression without the study drug. The FDA routinely accepts single-arm evidence for ultra-rare malignancies when: the disease has an established and poor natural history; the effect size (here, 69.7% CR/CRc versus historical rates well below this) is large enough to be interpretable without a concurrent control; and adequate regulatory designations (Breakthrough, Orphan) are in place. The CADENZA approval follows this same logic used for tagraxofusp in 2018 and for multiple other ultra-rare cancer approvals. The absence of a randomized comparator reflects the rarity of the disease, not a weakness in the evidence standard applied.

    Safety: What the Prescribing Information Covers

    Boxed warning: hepatotoxicity including hepatic veno-occlusive disease

    Decnupaz carries a boxed warning for hepatotoxicity, including hepatic veno-occlusive disease (VOD), also called sinusoidal obstruction syndrome. VOD is a serious condition in which small hepatic veins are obstructed, causing liver damage that can range from mild and self-limiting to severe and fatal. It is a recognized complication of certain chemotherapy regimens and stem cell transplantation conditioning and can be life-threatening when severe.

    The boxed warning means:

    • Liver function tests must be monitored before each dose and as clinically indicated throughout treatment
    • Dose modifications or discontinuation are required for significant hepatotoxicity
    • Patients proceeding to stem cell transplantation after Decnupaz require careful management of VOD risk in the transplant setting

    Warnings and precautions

    Infusion-related reactions (IRRs): Infusion-related reactions occurred in clinical trials. Patients should be premedicated per the prescribing information before each infusion and monitored throughout administration. For severe reactions, the infusion should be stopped and not restarted.

    Edema: Fluid retention and edema are documented with CD123-targeted therapies in BPDCN. Monitor for new or worsening edema, particularly in patients with baseline cardiac or renal disease.

    Sulfite allergic reactions: Decnupaz contains sodium metabisulfite, which can cause allergic-type reactions including anaphylaxis and bronchospasm in susceptible individuals. The risk is higher in patients with asthma. Patients should be asked about sulfite sensitivity before initiating therapy.

    Embryo-fetal toxicity: Based on the mechanism of action (DNA alkylation), Decnupaz can cause fetal harm. Females of reproductive potential should use effective contraception during treatment and for at least 6 months after the final dose. Males with female partners of reproductive potential should use effective contraception during treatment and for at least 4 months after the final dose.

    Dosing and Administration

    ParameterDetails
    Dose0.045 mg/kg intravenously once every 3 weeks (21-day cycle)
    Infusion durationApproximately 15 to 30 minutes
    Dose calculationBased on actual body weight
    CyclesContinue until disease progression or unacceptable toxicity
    FormulationLyophilized cake for injection; requires reconstitution prior to administration
    PremedicationPer prescribing information; required before each infusion

    What This Approval Means in Context

    Decnupaz vs. tagraxofusp

    Decnupaz is the second approved therapy for BPDCN. Tagraxofusp (Elzonris), approved in 2018, remains the reference treatment for newly diagnosed BPDCN and demonstrated an overall response rate of 90% in treatment-naive patients in its pivotal trial. However, tagraxofusp carries a boxed warning for capillary leak syndrome, a serious and potentially life-threatening vascular complication that limits its use in some patients.

    Decnupaz offers a mechanistically distinct option across both treatment-naive and relapsed settings, with a different toxicity profile. No head-to-head comparison between tagraxofusp and Decnupaz exists; the choice between them in the treatment-naive setting will depend on institutional experience, patient-specific factors including comorbidities that affect tolerance of each product’s boxed warning risks, and the treating hematologist’s clinical judgment.

    The approval of Decnupaz for relapsed or refractory disease is particularly significant because tagraxofusp’s pivotal data was primarily in the treatment-naive setting, and until now there has been no approved targeted therapy specifically for patients who have progressed after first-line treatment.

    The AbbVie acquisition context

    Pivekimab sunirine was originally developed by ImmunoGen, Inc., a company that pioneered ADC technology and developed multiple ADCs including mirvetuximab soravtansine (Elahere) for ovarian cancer. In early 2024, AbbVie acquired ImmunoGen for approximately $10.1 billion, a transaction that included pivekimab sunirine in the pipeline. The BLA for Decnupaz was submitted to the FDA in September 2025 and approved May 27, 2026.

    For Patients and Clinicians

    For patients diagnosed with BPDCN

    BPDCN is rare enough that most patients will be referred to specialized hematology centers with experience in this disease shortly after diagnosis. Treatment decisions for BPDCN, including the choice between Decnupaz and tagraxofusp in treatment-naive disease, and whether to pursue stem cell transplantation, belong with a board-certified hematologic oncologist familiar with this specific diagnosis.

    Decnupaz is now an FDA-authorized option for adults with BPDCN in any line of therapy. For patients who have relapsed after prior treatment, including tagraxofusp, this is the first approved targeted therapy available in that setting.

    The Leukemia and Lymphoma Society (LLS) and NORD maintain current clinical information on BPDCN including specialist referral resources. For clinical trial opportunities, ClinicalTrials.gov lists currently enrolling studies for BPDCN. AbbVie’s patient support program provides access resources for Decnupaz at abbvie.com/BPDCN.

    For related HED coverage of other ADC approvals and hematologic malignancy treatment advances in 2026, see our post on Inqovi plus venetoclax, the first all-oral AML regimen for treatment-ineligible patients, and our post on the Immgolis biosimilar approval and the TNF inhibitor market for autoimmune conditions.

    Sources

    FDA approval announcement: FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm, an ultra-rare hematologic malignancy. FDA.gov. May 27, 2026.

    AbbVie press release: AbbVie Announces FDA Approval of Decnupaz (pivekimab sunirine-pvzy) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. abbvie.com. May 27, 2026.

    Drugs.com approval news: FDA Approves Decnupaz (pivekimab sunirine-pvzy) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. drugs.com. May 27, 2026.

    ASCO Post clinical summary: BPDCN: FDA Approves Pivekimab Sunirine-pvzy. ascopost.com. May 2026.

    CancerNetwork detailed coverage: FDA Approves Pivekimab Sunirine in Rare Hematologic Malignancy. cancernetwork.com. May 2026.

    Targeted Oncology full trial summary: FDA Approves Pivekimab Sunirine for BPDCN. targetedonc.com. May 2026.

    OncLive OS data coverage: FDA Approves Pivekimab Sunirine for Blastic Plasmacytoid Dendritic Cell Neoplasm. onclive.com. May 2026.

    ONS clinical summary: FDA Approves Pivekimab Sunirine-Pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm. ons.org. May 2026.

    CURE magazine coverage: FDA OKs Decnupaz for Adults With Blastic Plasmacytoid Dendritic Cell Neoplasm. curetoday.com. May 2026.

    Medscape coverage: FDA Approves Novel Targeted Therapy for Rare Blood Cancer. medscape.com. May 2026.

    CADENZA trial registration: NCT03386513. ClinicalTrials.gov.

    Tagraxofusp FDA approval (reference): FDA approves tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm. FDA.gov. 2018.

    BPDCN disease overview: Blastic Plasmacytoid Dendritic Cell Neoplasm. StatPearls. NCBI.

    BPDCN GARD overview: Blastic Plasmacytoid Dendritic Cell Neoplasm. rarediseases.info.nih.gov.

    Hepatic VOD reference: Hepatic Veno-Occlusive Disease. PMC6016375.

    ADC overview: Antibody-Drug Conjugate. cancer.gov.

    Breakthrough Therapy Designation: Breakthrough Therapy. FDA.gov.

    Orphan Drug Designation: Designating an Orphan Product. FDA.gov.

    AbbVie acquisition of ImmunoGen: AbbVie Completes Acquisition of ImmunoGen. abbvie.com.

    Patient resources: Leukemia and Lymphoma Society: BPDCN | NORD: BPDCN | NIH GARD: BPDCN | ClinicalTrials.gov: BPDCN

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. BPDCN is an ultra-rare malignancy requiring specialist care. Treatment decisions should be made in close consultation with a board-certified hematologic oncologist with experience in rare blood cancers.
  • Linzess Is Now Approved for Children as Young as Two. Here Is What Parents and Pediatric Clinicians Need to Know About the First Prescription Therapy for Pediatric Functional Constipation in This Age Group.

    Linzess Is Now Approved for Children as Young as Two. Here Is What Parents and Pediatric Clinicians Need to Know About the First Prescription Therapy for Pediatric Functional Constipation in This Age Group.

    📌 The essentials On May 21, 2026, the FDA approved Linzess (linaclotide 72 mcg, Ironwood Pharmaceuticals/AbbVie) for functional constipation in pediatric patients aged 2 years and older. This expands Linzess’s prior pediatric FC approval (ages 6 and older, approved 2023) to now include children ages 2 to 5 years. Linzess remains the only FDA-approved prescription therapy for pediatric functional constipation. Clinical basis: a Phase 3 randomized, placebo-controlled, double-blind 12-week trial in patients aged 2 to 5 years with functional constipation, showing that linaclotide 72 mcg significantly increased spontaneous bowel movements versus placebo with a consistent safety profile. This approval was supported by efficacy data from the earlier Phase 3 trial in children aged 6 to 17 years published in The Lancet Gastroenterology and Hepatology. Complete Linzess pediatric FC indication: ages 2 to 17 years, 72 mcg once daily. Critical safety warning: Linzess is contraindicated in patients under 2 years of age due to the risk of serious dehydration based on neonatal animal data. This age floor is absolute. The most common adverse event in pediatric patients is diarrhea. Severe diarrhea requires discontinuation and rehydration. Linzess is not a laxative and should not be used in patients with known or suspected mechanical gastrointestinal obstruction.

    Functional constipation in children is one of the most common complaints seen in pediatric primary care and pediatric gastroenterology. It accounts for approximately 25% of all pediatric gastroenterology visits and up to 5% of all general pediatric office visits in the United States. For a condition that affects millions of children, the treatment options have been remarkably limited: behavioral and dietary interventions, over-the-counter osmotic laxatives like polyethylene glycol (MiraLAX), and in more refractory cases, office-based and specialist-managed regimens that still often fall short.

    Until 2023, there was no FDA-approved prescription drug specifically for functional constipation in children. That changed when linaclotide was approved for children aged 6 to 17 years. On May 21, 2026, the FDA extended that approval to children as young as 2, supported by a Phase 3 trial specifically designed and conducted in the 2-to-5 age group.

    This post covers what functional constipation is in children, how linaclotide works, what the evidence shows for the 2-to-5 age group, how to administer the drug in young children, and what the critical safety considerations are for parents and clinicians.

    What Functional Constipation Is and Why Young Children Are Particularly Affected

    Functional constipation is a clinical diagnosis based on symptoms rather than a structural or metabolic cause. In the pediatric population, it is defined using Rome IV criteria as the presence of at least two of the following symptoms over at least one month, without evidence of organic pathology:

    • Fewer than 3 spontaneous defecations per week
    • History of excessive stool retention or fecal withholding
    • History of painful or hard bowel movements
    • History of large-diameter stools that may obstruct the toilet
    • Presence of a large fecal mass in the rectum on examination

    The estimated worldwide prevalence in preschool-aged children is approximately 3%, though regional variation is substantial and the true prevalence may be higher given that many cases are managed at home without clinical contact. In the United States, functional constipation affects an estimated 1 in 20 young children at any given time.

    Why the 2-to-5 age group is particularly vulnerable

    Preschool-aged children are at elevated risk for functional constipation for several physiological and behavioral reasons. Toilet training is a common precipitant: the transition from diapers to toilet use can trigger withholding behaviors, particularly if a child associates the toilet with discomfort or anxiety. Any painful stool passage creates a cycle: pain leads to withholding, withholding leads to harder and larger stools, larger stools cause more pain on passage, which reinforces withholding further.

    Dietary transitions in this age group, including the shift to family foods, weaning from breast milk, and inconsistent fiber intake, also contribute. Limited communication ability in younger children means parents often underestimate the degree of discomfort or may not recognize withholding behaviors for what they are.

    Untreated functional constipation in young children has real consequences beyond discomfort. Chronic fecal retention can lead to fecal impaction, which may require emergency intervention. Encopresis (overflow fecal incontinence) can develop and carries significant social and psychological consequences for school-aged children. The earlier effective treatment is initiated, the lower the risk of this cascade.

    What the Rome IV criteria mean in practice for ages 2 to 5 For the youngest patients covered by the expanded Linzess indication, the Rome IV criteria for toddlers and preschoolers specifically recognize behaviors that are not always recognized as constipation by parents. Fecal withholding, in which a child deliberately tightens pelvic floor muscles and assumes characteristic postures to prevent defecation, is one of the most common presentations. Parents often mistake withholding postures for straining. The assessment of whether stools are hard, the frequency of natural bowel movements, and the presence of pain should all be evaluated in context of the child’s developmental stage, dietary history, and any identifiable precipitants. Organic causes of constipation in this age group that must be excluded before a functional diagnosis is made include Hirschsprung’s disease (rare but important), hypothyroidism, celiac disease, and anatomical abnormalities. A thorough evaluation by the pediatrician or pediatric gastroenterologist before initiating prescription therapy is appropriate.

    How Linzess Works: The GC-C Mechanism

    Linaclotide is a guanylate cyclase-C (GC-C) agonist. It is a 14-amino-acid peptide structurally similar to endogenous GC-C-activating peptides (guanylin and uroguanylin) that are produced naturally by intestinal epithelial cells.

    When linaclotide binds to GC-C receptors on the luminal surface of intestinal epithelial cells, it activates a signaling cascade that produces cyclic GMP (cGMP) inside those cells. Elevated intracellular cGMP activates a chloride and bicarbonate channel (CFTR) in the intestinal epithelium, which secretes fluid into the intestinal lumen. The resulting increase in luminal fluid content softens stool and accelerates intestinal transit.

    Locally elevated cGMP also activates pathways that reduce the activity of pain-sensing nerve fibers in the intestinal wall. This visceral analgesic effect is believed to contribute to reduced abdominal discomfort and pain associated with constipation, though the clinical relevance of this mechanism in pediatric patients has not been specifically established.

    Critically, linaclotide acts almost entirely in the gut. Systemic absorption is minimal: the drug is not measurably detected in the bloodstream at therapeutic doses. This limited absorption is one reason the pediatric side effect profile is favorable compared to systemically acting drugs.

    The Pediatric Evidence Base: What the Trials Showed

    Linzess’s expanded approval for ages 2 to 5 years builds on a pediatric evidence program that has been developed over several years.

    Phase 3 trial in children aged 6 to 17 (the foundational pediatric trial)

    The original pediatric FC indication (ages 6 to 17) was supported by data from Trial 7 (NCT04026113), a 12-week, double-blind, placebo-controlled, randomized, multicenter Phase 3 trial in 328 children aged 6 to 17 years meeting modified Rome III criteria for functional constipation, published in The Lancet Gastroenterology and Hepatology.

    Key results from Trial 7:

    OutcomeLinaclotide 72 mcgPlacebo
    Spontaneous bowel movement frequency rateSignificantly higherReference
    Patients with at least 1 SBM within 24 hours of first dose30.5%20.7% (p=0.043)
    Patients with at least 1 SBM within 48 hours of first dose56.7%38.4% (p=0.0009)
    Most common adverse event (diarrhea)4% (7 of 164)Lower rate
    Safety vs. adultsConsistent profile—

    Source: Di Lorenzo C, Khlevner J, Rodriguez-Araujo G, et al. Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. The Lancet Gastroenterology and Hepatology. 2023. doi:10.1016/S2468-1253(23)00396-8.

    Phase 3 trial in children aged 2 to 5 (the basis for the May 2026 expansion)

    The May 2026 approval for ages 2 to 5 was based on a Phase 3, 12-week, randomized, placebo-controlled trial specifically designed for this younger age group. This trial evaluated linaclotide 72 mcg in children aged 2 to 5 years with functional constipation, demonstrating that the drug significantly increased spontaneous bowel movements versus placebo with a consistent safety profile in this age range.

    The trial specifically confirmed that the mechanism is active in this age group: GC-C intestinal expression in children aged 2 to less than 18 years was examined in a clinical study and showed no age-dependent trend, providing the biological rationale for why the same dose produces consistent effects across the 2-to-17 age range. Below age 2, insufficient data on GC-C expression precludes safe use, which is the basis for the absolute age-2 lower limit.

    Both the pediatric 6-to-17 trial and the new 2-to-5 trial data are also supported by efficacy extrapolation from robust adult trials in chronic idiopathic constipation, providing multiple layers of evidence that the mechanism operates consistently.

    The Full Linzess Pediatric Approval Picture: A Rapidly Expanding Label

    The May 2026 approval is the most recent in a series of pediatric Linzess approvals that have expanded its use substantially since the original 2012 adult approval:

    IndicationPopulationApproval date
    Chronic idiopathic constipation (CIC)AdultsAugust 2012
    Irritable bowel syndrome with constipation (IBS-C)AdultsAugust 2012
    Functional constipation (FC)Pediatric patients aged 6 to 17 yearsSeptember 2023
    IBS-CPediatric patients aged 7 years and olderNovember 2025
    Functional constipation (FC) expandedPediatric patients aged 2 years and olderMay 21, 2026

    Linzess is now the only FDA-approved prescription drug for functional constipation in children from age 2 through age 17. It is also the first and only FDA-approved prescription therapy for IBS-C in children aged 7 and older.

    Dosing and Administration

    Recommended dose for all pediatric FC patients (ages 2 to 17): Linaclotide 72 mcg orally once daily.

    Timing: On an empty stomach, at least 30 minutes before the first meal of the day.

    Administration in young children (ages 2 to 5): Young children cannot swallow capsules whole. The capsule contents can be administered in two ways, as outlined in the prescribing information:

    • With applesauce: Open the capsule, sprinkle the contents onto one teaspoon of room-temperature applesauce, and have the child swallow the mixture immediately without chewing. Do not store the mixture.
    • With water: Open the capsule, pour the contents into a clean cup containing approximately 1 teaspoon (about 5 mL) of room-temperature water, gently swirl for approximately 20 seconds, and have the child swallow the mixture immediately. Do not store the mixture.

    Do not administer by crushing or dissolving the capsule itself. Do not add the contents to infant formula, breast milk, or beverages other than water.

    If a dose is missed: Take it as soon as possible on the same day. If that day has passed, skip the missed dose and resume the next day. Do not double up.

    Duration of therapy: The appropriate treatment duration should be determined by the prescribing clinician based on treatment response and the child’s clinical course. Functional constipation in young children can be a chronic, relapsing condition, and ongoing therapy may be appropriate in some children after other management strategies have been optimized.

    Safety: What Parents and Clinicians Need to Know

    Contraindication in patients under 2 years of age

    Linzess is absolutely contraindicated in patients younger than 2 years. In neonatal mouse studies, linaclotide caused increased fluid secretion through age-dependent elevated GC-C activity, which led to rapid and fatal dehydration. The 2-year minimum age reflects the human biological evidence that GC-C receptor expression does not show the same age-dependent elevation pattern in children 2 years and older, but insufficient data exists for those under 2 to confirm equivalent safety.

    This is not a soft guideline. It is an absolute contraindication with an FDA boxed-equivalent warning.

    Diarrhea: the most important adverse event to monitor

    Diarrhea is the most commonly reported adverse reaction in both adult and pediatric clinical trials. In the pediatric 6-to-17 trial (Trial 7), diarrhea occurred in 4% of linaclotide-treated patients compared with lower rates in the placebo arm. In younger children, dehydration risk from diarrhea is proportionally higher than in older patients because of lower total body water reserves.

    What to do if diarrhea occurs:

    • Mild diarrhea: monitor hydration closely; ensure the child is drinking fluids
    • Severe diarrhea: discontinue Linzess immediately and ensure adequate rehydration; contact the prescribing clinician

    Parents should be counseled specifically about diarrhea recognition and the dehydration signs in young children before starting therapy: decreased urine output, dry mucous membranes, reduced tears, and decreased activity level are clinical indicators of dehydration requiring medical evaluation.

    Mechanical obstruction: do not use in obstruction

    Linzess is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction. All patients should be evaluated for structural causes of constipation before initiating therapy.

    Systemic absorption: minimal

    Because linaclotide is minimally absorbed into the bloodstream, it does not produce systemic drug effects at therapeutic doses. The safety profile reflects predominantly local GI effects rather than systemic medication reactions.

    What This Means for Parents Navigating Functional Constipation in a Young Child

    When to consider discussing Linzess with your pediatrician

    Linzess is a prescription medication intended for children with functional constipation who have not responded adequately to dietary and behavioral interventions and to over-the-counter laxative therapy (such as polyethylene glycol). It is not a first-line treatment for all constipation in young children, and most children will begin with simpler, less intensive approaches.

    A conversation about Linzess is appropriate when:

    • Your child ages 2 to 5 has been diagnosed with functional constipation by a pediatrician or pediatric gastroenterologist
    • You have tried dietary modification (increased fluid and fiber intake), toilet training adjustments, and at least one course of over-the-counter osmotic laxative therapy
    • Constipation continues to affect your child’s quality of life, comfort, or daily functioning despite these approaches
    • Your pediatrician has excluded organic causes of constipation appropriate to your child’s age

    How to administer to a toddler or preschooler

    The applesauce administration method is typically easiest for most children ages 2 to 5. The granules from the capsule are nearly tasteless, and mixing them into a small amount of applesauce is usually well-accepted. If your child does not tolerate applesauce, the water slurry method is available. Consistency in daily timing (before breakfast each morning) helps establish the routine.

    What to watch for during the first weeks of therapy

    In the first 1 to 4 weeks, parents should monitor for:

    • Improvement in bowel movement frequency and stool consistency (the expected benefit)
    • Diarrhea or loose stools (the most common side effect; mild cases may not require stopping the drug)
    • Signs of dehydration if diarrhea occurs (reduced wet diapers or urination, dry mouth, no tears when crying, unusual lethargy)
    • Worsening of abdominal discomfort or new symptoms that were not present before starting

    Keep your pediatrician informed of the response within the first 4 weeks. If your child has not shown improvement in spontaneous bowel movement frequency and stool consistency after a reasonable trial period, discuss with your provider whether continuing therapy is appropriate.

    For related HED coverage of gastrointestinal health and gut-targeted drug approvals, see our post on Lynavoy (linerixibat) for cholestatic pruritus in primary biliary cholangitis, which covers another gut-targeted therapy approval, and our post on the Fasenra approval for hypereosinophilic syndrome as an example of how rare condition approvals are expanding across pediatric populations in 2026.

    Sources

    FDA approval announcement: FDA Approves Use of LINZESS (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC). FDA.gov. May 21, 2026.

    Ironwood Pharmaceuticals press release: FDA Approves Use of LINZESS (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation. investor.ironwoodpharma.com. May 27, 2026.

    BioSpace press release: FDA Approves Use of LINZESS (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation. biospace.com. May 2026.

    Drugs.com approval news: FDA Approves Linzess (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation. drugs.com. May 2026.

    HCPLive clinical coverage: FDA Approves Linaclotide (Linzess) for Functional Constipation in Patients 2 Years and Older. hcplive.com. May 2026.

    Conexiant/Pediatrics clinical news: FDA OKs Linaclotide in Young Children. conexiant.com. May 2026.

    Phase 3 Trial 7 primary publication (Lancet GH): Di Lorenzo C, Khlevner J, Rodriguez-Araujo G, et al. Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. The Lancet Gastroenterology and Hepatology. 2023. doi:10.1016/S2468-1253(23)00396-8.

    Trial 7 registration: NCT04026113. ClinicalTrials.gov.

    FDA first pediatric FC approval press release (September 2023): FDA Approves First Treatment for Pediatric Functional Constipation. FDA.gov. September 2023.

    FDA pediatric IBS-C approval (November 2025): FDA Approves First Drug for Children 7 Years and Older with Irritable Bowel Syndrome with Constipation. FDA.gov. November 2025.

    Linzess prescribing information: LINZESS (linaclotide) Prescribing Information. Ironwood Pharmaceuticals/AbbVie. Updated 2026.

    Functional constipation in children (NIDDK): Constipation in Children. niddk.nih.gov.

    Functional constipation StatPearls: Functional Constipation. StatPearls. NCBI.

    Linaclotide mechanism: Linaclotide. StatPearls. NCBI.

    GC-C receptor biology: Guanylate Cyclase-C in GI Tract. PMC4415491.

    Patient resources: North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) | NIDDK Constipation in Children | Linzess patient resources

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Linzess (linaclotide) is a prescription medication. Decisions about treatment for pediatric functional constipation, including the appropriateness of prescription therapy, should be made in consultation with a qualified pediatrician or pediatric gastroenterologist. Do not administer Linzess to children under 2 years of age.
  • The Only Drug Ever Approved in the United States for Hepatitis Delta Is Now Available. Here Is What Hepcludex Is and What the MYR301 Trial Data Shows.

    The Only Drug Ever Approved in the United States for Hepatitis Delta Is Now Available. Here Is What Hepcludex Is and What the MYR301 Trial Data Shows.

    📌 The essentials On May 22, 2026, the FDA approved Hepcludex (bulevirtide-gmod, Gilead Sciences), making it the first and only FDA-approved treatment for chronic hepatitis delta virus (HDV) infection in the United States. HDV has had no approved pharmacologic therapy in the United States for the entire history of its recognition as a disease. Indication: adults with chronic HDV infection without cirrhosis or with compensated cirrhosis. Regulatory pathway: accelerated approval based on a decrease in HDV RNA and alanine aminotransferase (ALT) normalization. Continued approval may be contingent on verification of clinical benefit in a confirmatory trial. Regulatory designations: Breakthrough Therapy Designation, Orphan Drug Designation, Priority Review. The clinical basis: Phase 3 MYR301 trial (NCT03852719), 150 patients with chronic HDV infection, published in the New England Journal of Medicine. Primary endpoint at week 48: combined response rate of 48% with bulevirtide 8.5 mg versus 2% with delayed treatment. Through 144 weeks: undetectable HDV RNA in 50% of treated patients. No treatment resistance detected through the full 144-week treatment period. Critical safety warning: a boxed warning for severe acute exacerbations of hepatitis B and HDV after discontinuation. Do not stop Hepcludex without medical supervision. Dosing: 8.5 mg subcutaneous injection once daily. European status: bulevirtide 2 mg was approved in the European Economic Area in 2020; the 8.5 mg dose used in the U.S. approval was the dose studied in MYR301’s pivotal arm.

    Hepatitis delta virus is the rarest and most severe of the five major viral hepatitis types. It can only infect people who also have hepatitis B, because it is a satellite virus that needs the hepatitis B surface antigen to enter liver cells. In people with this coinfection, liver disease progresses faster, cirrhosis develops earlier, and the risks of liver cancer and liver-related death are substantially higher than with hepatitis B alone.

    Despite this severity, and despite HDV being recognized for decades, there has never been an FDA-approved treatment for it in the United States. Clinicians have managed it with off-label, interferon-based regimens that are effective in a minority of patients, carry significant toxicity, and are not suitable for many patients with advanced liver disease.

    That changed on May 22, 2026, when the FDA approved Hepcludex (bulevirtide-gmod) as the first approved treatment for chronic HDV in the United States. It is a first-in-class entry inhibitor that works through a mechanism unlike anything previously approved for viral hepatitis, and its approval is the culmination of a Phase 3 trial program that has generated eight years of clinical data across multiple dose levels and treatment durations.

    What Hepatitis Delta Is and Why It Has Been So Hard to Treat

    The biology of HDV and its relationship to HBV

    Hepatitis delta virus (HDV) is a defective RNA virus discovered in 1977 by Mario Rizzetto in Italy. It is classified as a satellite virus: it cannot replicate independently. To enter hepatocytes (liver cells), it requires the hepatitis B surface antigen (HBsAg), which sits on the outer envelope of hepatitis B virus (HBV) particles and is also expressed on HDV virions. Without HBsAg, HDV cannot infect new cells.

    This dependency means HDV only infects people who are already HBV-infected, either as a co-infection at the same time as HBV or as a superinfection in a person already chronically infected with HBV. Superinfection is the more clinically dangerous scenario: a person with chronic HBV who becomes superinfected with HDV typically develops accelerated liver disease.

    The HDV genome encodes only one protein: the delta antigen (HDAg), in small and large isoforms. The small form promotes viral RNA replication; the large form suppresses replication and is required for virion assembly. This minimal genome is why HDV replicates so efficiently inside HBV-infected cells without needing to encode its own machinery.

    The clinical consequence of HDV coinfection

    In patients with chronic HBV/HDV coinfection, the presence of HDV dramatically accelerates liver injury. Compared to HBV monoinfection:

    • Cirrhosis develops significantly faster, with some studies showing the median time to cirrhosis cut by half or more
    • Hepatocellular carcinoma (HCC) occurs at 2 to 3 times the rate
    • Liver-related mortality is substantially higher
    • The risk of developing end-stage liver disease requiring transplantation is elevated

    Chronic HDV infection is now recognized as the most severe form of viral hepatitis, carrying a worse prognosis than hepatitis B, C, or other viral types.

    How many people are affected and why it is underrecognized Global prevalence estimates for chronic HDV infection range from 12 million to 72 million people worldwide, reflecting genuine uncertainty in epidemiological data because HDV testing is inconsistently performed. In the United States, estimates suggest approximately 100,000 people are living with chronic HDV infection, though the true number is likely higher because HDV testing is not routinely performed in all HBV-infected patients. HDV disproportionately affects people who inject drugs (where percutaneous transmission is efficient), immigrants from regions with high HBV/HDV endemicity (Mongolia, West Africa, Eastern Europe, the Amazon basin), and people in populations with high HBV prevalence. The gap between actual prevalence and diagnosed cases reflects both under-testing and the relative rarity of the condition in clinical training curricula. Many HBV patients are never tested for HDV despite guidelines recommending HDV testing in high-risk individuals.

    How Bulevirtide Works: The Entry Inhibitor Mechanism

    Bulevirtide is a first-in-class viral entry inhibitor. No previously approved hepatitis drug has worked through this mechanism. Understanding it requires understanding how HBV and HDV enter liver cells.

    Both HBV and HDV use the same receptor to enter hepatocytes: sodium taurocholate cotransporting polypeptide (NTCP), a bile acid transporter expressed on the surface of liver cells. The viral entry process begins when a region of the HBV pre-S1 domain on the outer envelope of the virus binds to NTCP with high affinity. This binding triggers the virus to be taken up into the hepatocyte.

    Bulevirtide is a myristoylated synthetic peptide, meaning it is a short chain of amino acids with a fatty acid (myristic acid) attached that anchors the molecule in cell membranes. Its amino acid sequence mimics the pre-S1 region that HBV and HDV use to bind NTCP. By competing with the virus for NTCP binding, bulevirtide prevents both HBV and HDV from entering hepatocytes, reducing the number of infected cells over time.

    This is a mechanistically rational and highly targeted approach. It does not work inside the cell on the viral replication machinery, like nucleoside analogs for HBV. It works outside the cell, at the entry step, blocking new infection events. As old infected hepatocytes naturally die and are replaced, and as new cells are protected from infection, the proportion of HDV-infected hepatocytes in the liver declines.

    Illustration of Hepcludex mechanism of action

    The important implication: bulevirtide must be taken daily on a long-term basis, because stopping the drug removes the competitive blockade of NTCP, allowing HDV and HBV to resume infecting new hepatocytes. This pharmacological characteristic directly explains the boxed warning for severe exacerbation after discontinuation.

    The MYR301 Trial: Design and Full Results

    Design

    MYR301 (NCT03852719) is a multicenter, randomized, open-label, parallel-arm Phase 3 trial evaluating the long-term efficacy and safety of bulevirtide in adults with chronic HDV. The trial enrolled 150 patients who were randomized 1:1:1 to three arms:

    • Bulevirtide 2 mg once daily for 144 weeks (n=49)
    • Bulevirtide 10 mg once daily for 144 weeks, which is approximately equivalent to the 8.5 mg U.S. approved dose (n=50)
    • Delayed treatment: 48-week observational period (no antiviral treatment for HDV) followed by bulevirtide 10 mg once daily for 96 weeks (n=51)

    The delayed treatment arm served as the control for the primary endpoint analysis. After 48 weeks, all delayed-treatment patients crossed over to receive bulevirtide. This design was used because withholding all treatment for 144 weeks in a condition as severe as HDV was not considered ethically appropriate.

    The trial has continued through a 96-week off-treatment follow-up period, generating the longest dataset available for any HDV therapeutic program.

    Primary endpoint: week 48 combined response

    The primary efficacy endpoint was combined response at week 48, defined as both:

    • Undetectable HDV RNA OR a decline in HDV RNA of 2 log10 IU/mL or greater from baseline, AND
    • Normalization of alanine aminotransferase (ALT)
    Outcome at Week 48Bulevirtide (10 mg arm)Delayed treatment (control)
    Combined response rate48%2%
    Undetectable HDV RNA20%0%
    ALT normalizationIncluded in combined responseMinimal improvement
    Statistical significancep less than 0.001Reference

    Source: Wedemeyer H et al. A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D. New England Journal of Medicine. 2023;389:22-32. doi:10.1056/NEJMoa2213429.

    The 46-percentage-point difference between the active treatment arm (48%) and the delayed treatment arm (2%) is the formal basis for the accelerated approval. The 2% rate in the delayed treatment arm is a direct reflection of HDV’s natural history: without treatment, spontaneous virologic suppression in chronic HDV is extremely rare.

    Deepening response over time: through 144 weeks

    One of the most clinically informative aspects of MYR301 is its long-term follow-up data, which was available to the FDA as part of the approval package.

    Virologic response over timeBulevirtide (immediate treatment arm)
    Undetectable HDV RNA at Week 4820%
    Undetectable HDV RNA at Week 9636%
    Undetectable HDV RNA at Week 14450%
    Combined response at Week 96Improved from Week 48
    Treatment resistance detectedNone through 144 weeks
    Patients with suboptimal early response at Week 24 who achieved virologic response by Week 9643% of non-responders; 82% of partial responders

    Source: Journal of Hepatology 2024. doi:10.1016/j.jhep.2024.05.021. Gilead press release. May 2025.

    The trajectory from 20% undetectable at week 48 to 50% undetectable at week 144 is the central efficacy message of the long-term MYR301 data. Patients who continue on bulevirtide are increasingly likely to achieve complete virologic suppression over time. This deepening response is consistent with the mechanism: as more cycles of hepatocyte replacement occur under entry inhibition, the proportion of infected cells progressively declines.

    The absence of treatment resistance through 144 weeks is a notable finding. In HIV and HBV medicine, selection for resistance mutations under antiviral pressure is a persistent challenge. Bulevirtide’s mechanism as a host-targeting entry inhibitor rather than a direct-acting antiviral targeting viral enzymes may contribute to the absence of resistance.

    Off-treatment durability

    Final data from MYR301, presented in 2025, showed that 90% of patients who had achieved undetectable HDV RNA at the end of treatment (144 weeks) remained undetectable for nearly two years off treatment. This durability after stopping therapy is an important finding for patients who want to understand what long-term treatment success might look like.

    Why combined response (virologic plus biochemical) is the right endpoint for HDV In chronic viral hepatitis, virologic suppression alone does not capture the full clinical picture. ALT normalization reflects reduction in active liver inflammation: elevated ALT indicates ongoing hepatocyte injury, and its normalization suggests that the liver injury driven by active HDV replication is being controlled. The FDA required both components in the primary endpoint because treatment with HDV antivirals can suppress viral replication (virologic response) without fully resolving the inflammatory liver injury (biochemical response), and the combination captures both dimensions of disease activity that matter for long-term liver health. This is why the 48% combined response rate, rather than just the virologic response rate, is the appropriate headline number from MYR301.

    Safety: What the Prescribing Information Covers

    Boxed warning: severe acute exacerbations after discontinuation

    Hepcludex carries a boxed warning for severe acute exacerbations of hepatitis B and HDV after stopping treatment. When bulevirtide is discontinued, NTCP receptors that were competitively blocked by the drug become available again, allowing HBV and HDV to rapidly resume infecting hepatocytes. In some patients, this viral rebound produces a sudden, severe flare of hepatitis that can be clinically dangerous.

    This warning has direct clinical implications for prescribers and patients:

    • Do not stop Hepcludex without discussing a discontinuation plan with your hepatologist
    • If discontinuation is necessary (surgery, tolerability issue, non-adherence), patients require close monitoring of liver function tests and HDV RNA for a minimum of 24 weeks after stopping
    • Patients should be counseled about this risk before starting treatment to ensure informed decision-making about the long-term nature of therapy

    Serious adverse reactions

    • Hypersensitivity reactions including anaphylaxis: Reported with bulevirtide. Monitor for signs of allergic reaction after each injection, especially during the initial treatment period.
    • Bile acid transporter inhibition: Because bulevirtide blocks NTCP, which is a bile acid transporter in addition to being the HBV/HDV entry receptor, it elevates circulating bile acid concentrations in the blood. This is a pharmacological consequence of the mechanism. In MYR301, elevated bile acids were observed and were generally asymptomatic, but the clinical implications of chronic NTCP inhibition with respect to bile acid metabolism are monitored as part of the drug’s safety profile.

    Common adverse reactions

    The most commonly reported adverse reactions in MYR301 were headache, abdominal pain, fatigue, pruritus (itching), and injection site reactions. Adverse events were mostly mild in severity, with no serious adverse events related to bulevirtide reported through 96 weeks of treatment.

    Dosing and Administration

    Approved dose: 8.5 mg as a subcutaneous injection once daily.

    Administration: The drug is supplied as a lyophilized powder for injection. After reconstitution, the solution is administered as a subcutaneous injection. Patients can be trained to self-inject.

    Duration: MYR301 treated patients for up to 144 weeks. The approved label does not specify a fixed treatment duration, consistent with the evolving evidence on long-term response and the expectation that patients who respond well may continue treatment.

    Timing relative to other medications: Because bulevirtide blocks NTCP, it should not be taken simultaneously with medications that depend on NTCP for their hepatic uptake. Notable interactions include teriflunomide and some statins. Review the full prescribing information for the complete drug interaction list before prescribing.

    HBV management: Most patients with HDV are also being managed for HBV with oral antivirals (entecavir, tenofovir). HBV suppression therapy is typically continued alongside bulevirtide; bulevirtide does not replace HBV antiviral management.

    The Regulatory Journey: Why This Took So Long and What Changed

    Bulevirtide has been in development for nearly a decade. It received European Medicines Agency approval for 2 mg use in the European Economic Area in July 2020, making it available to European patients more than five years before U.S. approval. The delay in U.S. approval reflected the FDA’s requirement for robust Phase 3 controlled data from a U.S.-eligible trial, which MYR301 was designed to provide.

    The drug received multiple FDA designations recognizing the seriousness of HDV and the absence of alternatives:

    The accelerated approval was granted on the basis that combined virologic and biochemical response is reasonably likely to predict long-term clinical benefit, specifically a reduction in the risk of cirrhosis, liver failure, and hepatocellular carcinoma. Confirmation of that clinical benefit in a dedicated outcomes trial is required as a post-marketing commitment.

    What This Means for Patients With Chronic HDV Infection

    For patients currently diagnosed with HDV

    Hepcludex is now available in the United States for adults with chronic HDV infection without cirrhosis or with compensated cirrhosis. If you have been diagnosed with chronic HDV coinfection, this is the first FDA-approved therapy you can discuss with your hepatologist.

    The most important questions to raise with your provider:

    • Is my cirrhosis status (absent, compensated, or decompensated) consistent with the approved indication?
    • What is my current HBV management regimen, and how will it interact with bulevirtide?
    • What is my baseline HDV RNA and ALT level, which will serve as the reference point for monitoring treatment response?
    • What is the monitoring schedule for HDV RNA, ALT, and bile acid levels during treatment?
    • What is the plan if I need to stop treatment for any reason?

    For patients who have not yet been tested for HDV

    If you have chronic hepatitis B and have never been tested for HDV, and you fall into any of the higher-risk groups for HDV exposure (history of injection drug use, immigration from or travel to a high-prevalence region, or sexual contact with someone who has HDV), ask your hepatologist or primary care provider about HDV testing. The test is straightforward: an HDV antibody test initially, followed by HDV RNA if the antibody is positive.

    The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) both recommend HDV testing in patients with chronic HBV and risk factors for HDV exposure. Many patients with HDV are currently undiagnosed.

    Patient support

    Gilead’s Support Path program provides resources to help patients and healthcare professionals navigate coverage and financial assistance for Hepcludex. The Hepatitis B Foundation and the American Liver Foundation both maintain patient-facing resources on viral hepatitis management including HDV. The Global Hepatitis Delta Partnership is an international patient advocacy organization specifically focused on HDV.

    For related HED coverage of other liver disease treatment approvals in 2026, see our post on Lynavoy (linerixibat) for cholestatic pruritus in primary biliary cholangitis and our post on Tavneos (avacopan) and the serious liver injury warning that has put the FDA and Amgen at odds.

    Sources

    FDA press announcement: FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection. FDA.gov. May 22, 2026.

    Gilead Sciences press release: FDA Grants Accelerated Approval to Gilead’s Hepcludex (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV). businesswire.com. May 22, 2026.

    Drugs.com approval news: FDA Grants Accelerated Approval to Hepcludex (bulevirtide-gmod) for Chronic Hepatitis Delta Virus (HDV). drugs.com. May 22, 2026.

    MYR301 primary NEJM publication: Wedemeyer H et al. A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D. New England Journal of Medicine. 2023;389:22-32. doi:10.1056/NEJMoa2213429.

    MYR301 week 96 Journal of Hepatology publication: Wedemeyer H et al. Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial. J Hepatol. 2024. doi:10.1016/j.jhep.2024.05.021.

    MYR301 final 144-week data (Gilead press release): Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability. gilead.com. May 2025.

    MYR301 trial registration: NCT03852719. ClinicalTrials.gov.

    Pharmacy Times clinical review: FDA Approves Bulevirtide-gmod as First-Ever Treatment for Chronic Hepatitis Delta Virus Infection. pharmacytimes.com. May 2026.

    HCPLive clinical coverage: Bulevirtide Receives Historic First FDA Approval for Chronic Hepatitis Delta. hcplive.com. May 2026.

    Contagion Live approval summary: Bulevirtide Approved as First US Treatment for Chronic Hepatitis Delta Virus. contagionlive.com. May 2026.

    EMA Hepcludex EPAR: Hepcludex: European Public Assessment Report. ema.europa.eu.

    HDV biology overview: Hepatitis Delta Virus. StatPearls. NCBI.

    Bulevirtide mechanism (NTCP): Sodium Taurocholate Cotransporting Polypeptide as a Drug Target. PMC9283099.

    NIDDK hepatitis D overview: Hepatitis D. NIDDK.

    FDA accelerated approval: Accelerated Approval Program. FDA.gov.

    FDA breakthrough therapy: Breakthrough Therapy Designation. FDA.gov.

    FDA orphan drug: Designating an Orphan Product. FDA.gov.

    Hepcludex prescribing information: Hepcludex (bulevirtide-gmod) Prescribing Information. Gilead Sciences. 2026.

    Patient resources: American Association for the Study of Liver Diseases | Hepatitis B Foundation | American Liver Foundation | Global Hepatitis Delta Partnership | Gilead Support Path Program

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Hepcludex received accelerated approval; continued approval may be contingent on confirmatory trial results. Do not start or stop Hepcludex without guidance from a qualified hepatologist. Treatment decisions for chronic HDV infection should be made in close consultation with a physician experienced in viral hepatitis management.

  • Datroway Is Now FDA-Approved for Immunotherapy-Ineligible Metastatic TNBC. Here Is What the TROPION-Breast02 Data Shows and What the Accelerated Approval Means.

    Datroway Is Now FDA-Approved for Immunotherapy-Ineligible Metastatic TNBC. Here Is What the TROPION-Breast02 Data Shows and What the Accelerated Approval Means.

    ✅ Updated May 26, 2026: FDA Approval Confirmed On May 22, 2026, the FDA approved Datroway (datopotamab deruxtecan-dlnk, AstraZeneca/Daiichi Sankyo) for adults with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. This is the first TROP2-directed ADC approved in this setting and the first targeted therapy to demonstrate a statistically significant overall survival advantage over chemotherapy in first-line immunotherapy-ineligible metastatic TNBC. Important regulatory note: this indication was approved under accelerated approval based on objective response rate (63% vs. 29%) and duration of response (12.3 vs. 7.1 months) as the regulatory basis. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. The PFS and OS data from TROPION-Breast02 (detailed below) provide the broader efficacy context but are not the formal basis of this particular approval. NCCN update: Following the approval, Datroway was added to the NCCN Clinical Practice Guidelines as a Category 1 preferred first-line treatment option for metastatic TNBC patients who are not candidates for immunotherapy. Global status: As of May 22, 2026, regulatory reviews are ongoing in the EU, China, Japan, Australia, Canada, Singapore, and Switzerland. Datroway’s full approved indication list now includes: HR-positive, HER2-negative metastatic breast cancer (approved January 2025); EGFR-mutated NSCLC after prior EGFR-directed therapy and platinum chemotherapy (accelerated approval); and metastatic TNBC ineligible for PD-1/PD-L1 inhibitor therapy (approved May 22, 2026, accelerated approval).

    Triple-negative breast cancer is defined by what it lacks: no estrogen receptor, no progesterone receptor, no HER2 amplification. Those absences mean that the targeted therapies which have transformed outcomes in other breast cancer subtypes do not apply here. For decades, chemotherapy was the only systemic option. Then, in 2020, immunotherapy arrived for patients whose tumors expressed the PD-L1 protein. A meaningful advance for those patients. But not everyone qualifies.

    Patients with metastatic TNBC who are ineligible for immunotherapy have historically had the fewest options and the worst outcomes of any breast cancer population. Their first-line treatment has remained standard cytotoxic chemotherapy, with all the toxicity that entails and a median overall survival below two years.

    Datopotamab deruxtecan (Dato-DXd, brand name Datroway) is now seeking to change that. Developed by AstraZeneca and Daiichi Sankyo, the drug already received FDA approval in January 2025 for a different breast cancer subtype (HR-positive, HER2-negative). Now it has Priority Review for a new indication: first-line treatment of metastatic TNBC in patients who are not candidates for immunotherapy. The PDUFA date falls in Q2 2026. The Phase 3 TROPION-Breast02 trial, published in the Annals of Oncology in April 2026, produced results that oncologists are calling a potential new standard of care.

    Triple-Negative Breast Cancer: The Biology, the Burden, and the Disparities

    Triple-negative breast cancer accounts for approximately 15% of all breast cancer diagnoses in the United States, roughly 35,000 new cases per year. Despite representing a minority of breast cancer cases, it accounts for a disproportionate share of breast cancer deaths because of its aggressive biology, its relative resistance to treatment, and its tendency to be diagnosed at younger ages and at more advanced stages.

    The racial disparities in TNBC are well documented and clinically significant. Black women are diagnosed with TNBC at roughly twice the rate of white women. They are more likely to be diagnosed at younger ages and more advanced stages. And despite these higher incidence rates, access to specialist oncology care and novel therapies has historically been unequal. Any advance in TNBC outcomes is therefore not just an oncologic milestone but a health equity issue.

    Who is ineligible for immunotherapy in TNBC, and why this population matters Since 2020 and 2021, PD-L1 checkpoint inhibitors (atezolizumab and then pembrolizumab) have been approved as first-line options for metastatic TNBC. Pembrolizumab with chemotherapy is now the standard of care for PD-L1-positive metastatic TNBC, and it produces a meaningful survival benefit in that population. However, PD-L1 positivity is not universal in TNBC. Depending on the assay and scoring method used, approximately 40 to 60 percent of metastatic TNBC patients have PD-L1-positive tumors. The remainder, along with patients who cannot receive immunotherapy due to autoimmune disease, organ transplant status, or other contraindications, fall into the immunotherapy-ineligible category. TROPION-Breast02 enrolled specifically and exclusively these patients. This is the population for which first-line treatment has remained unchanged at standard chemotherapy for decades, and the population for which Dato-DXd is seeking approval.

    What Is Dato-DXd and How Does It Work?

    Datopotamab deruxtecan is an antibody-drug conjugate, part of the same drug class as trastuzumab deruxtecan (Enhertu/T-DXd) and sacituzumab govitecan (Trodelvy). All ADCs share the same general architecture: an antibody that recognizes a target protein on cancer cell surfaces, linked to a chemotherapy payload. The antibody finds the cancer cell, binds to it, is internalized, and releases the payload inside the cell.

    Dato-DXd’s target is TROP2 (trophoblast cell-surface antigen 2), a protein expressed at high levels on the surface of many solid tumors, including the majority of TNBC tumors. The payload is DXd, a topoisomerase I inhibitor derived from exatecan. When the ADC is internalized into TROP2-expressing tumor cells, the linker is cleaved and DXd is released inside the cell, interfering with DNA replication and causing cancer cell death.

    The linker technology is an important distinguishing feature. The cleavable tetrapeptide-based linker used in Dato-DXd is designed to be stable in the bloodstream but cleaved efficiently inside cells. This stability reduces off-target payload release in circulation, which contributes to a lower rate of hematologic toxicity compared to some earlier ADC platforms. The same DXd payload and linker technology is used in T-DXd (Enhertu), which explains the shared class safety signal of interstitial lung disease and stomatitis across both drugs.

    Dato-DXd versus sacituzumab govitecan (Trodelvy): both target TROP2, but differently Sacituzumab govitecan (Trodelvy) is the other FDA-approved TROP2-directed ADC in breast cancer. It is approved for previously treated metastatic TNBC and for HR-positive HER2-negative metastatic breast cancer. Both it and Dato-DXd target TROP2, but they use different antibodies, different payloads (SN-38 for sacituzumab vs. DXd for datopotamab), and different linker technologies. The practical difference shows up in the safety profile: sacituzumab govitecan has higher rates of hematologic toxicity (neutropenia, diarrhea) while Dato-DXd’s signature toxicities are stomatitis and ocular surface events. Neither has been compared head-to-head in TNBC. They occupy different approved settings, and the question of how to sequence them in the metastatic TNBC treatment landscape is one the field will need to work out as approvals evolve. The panel discussion at OncLive noted that differences in linker technology and payload between the two drugs may influence clinical outcomes, but no definitive comparative data exists. Clinicians should be familiar with both safety profiles to counsel patients appropriately.

    TROPION-Breast02: Design and Full Results

    Trial design

    TROPION-Breast02 (NCT05374512) was a randomized, open-label, international Phase 3 trial conducted across multiple countries. Between May 2022 and June 2024, 644 patients with previously untreated, locally recurrent inoperable or metastatic TNBC who were not candidates for PD-1/PD-L1 inhibitors were randomized 1:1 to Dato-DXd (6 mg/kg intravenously every 3 weeks, n=323) or investigator’s choice of chemotherapy (ICC, n=321). ICC options included paclitaxel, nab-paclitaxel, carboplatin, capecitabine, or eribulin mesylate. Randomization was stratified by geographic region, disease-free interval, and PD-L1 status.

    The trial had dual primary endpoints: progression-free survival by blinded independent central review (BICR) per RECIST 1.1, and overall survival. Both primary endpoints were required to demonstrate statistical significance for the trial to be considered successful. Achieving both is a notable distinction in a disease setting where OS data is often immature at the time of initial analysis.

    Efficacy results

    Efficacy endpointDato-DXd (n=323)Chemotherapy (n=321)
    Median PFS (BICR)10.8 months (95% CI 8.6–13.0)5.6 months (95% CI 5.0–7.0)
    PFS hazard ratio0.57 (95% CI 0.47–0.69; p<0.0001)Reference
    Risk reduction in progression/death43%Reference
    12-month PFS rate45.6%25.6%
    18-month PFS rate32.7%16.8%
    Median OS23.7 months18.7 months
    OS hazard ratio0.79 (21% reduction in risk of death; p<0.05)Reference
    Median treatment duration6.7 months4.1 months
    Patients on treatment at data cutoffLonger than chemo armShorter duration

    Source: Dent RA et al. Annals of Oncology. 2026 Apr 3. doi:10.1016/j.annonc.2026.03.008. Presented at ESMO Congress 2025, Berlin (Abstract LBA21).

    The PFS result is the most striking number: 10.8 versus 5.6 months is a near doubling of the time to disease progression or death. The 12-month PFS rates tell a related story: at one year, 45.6% of patients on Dato-DXd were progression-free, compared to 25.6% on chemotherapy. At 18 months, those rates were 32.7% versus 16.8%.

    The OS result of 23.7 versus 18.7 months represents approximately five additional months of survival, with a statistically significant hazard ratio of 0.79. Having both PFS and OS meet statistical significance in the same trial is an important finding. Many oncology trials achieve PFS endpoints but fail to translate that into an OS benefit, sometimes because subsequent therapies after disease progression equalize outcomes across arms. TROPION-Breast02 demonstrated both.

    The 6.7 versus 4.1 month median treatment duration favoring Dato-DXd is an indirect measure of tolerability: patients stayed on the experimental treatment longer, suggesting the drug was manageable enough to continue. That observation is supported by the safety data.

    For patients with ER-positive disease, a separate PROTAC-based therapy is simultaneously under FDA review. Read about it here.

    Safety: A Different Toxicity Profile Than Chemotherapy

    Dato-DXd does not look like chemotherapy in its safety profile. Where chemotherapy predominantly causes hematologic toxicity (neutropenia, anemia, febrile neutropenia), Dato-DXd’s characteristic adverse effects are mucosal (stomatitis) and ocular. This difference matters for patient counseling and clinical management.

    Safety metricDato-DXdChemotherapy (ICC)
    Any treatment-related adverse event93%83%
    Grade 3 or higher TRAEs33%29%
    Serious treatment-related AEs9%8%
    Discontinuation due to TRAEs4%7%
    Treatment-related deaths00
    Stomatitis (all grade)57%Lower
    Nausea (all grade)45%Lower
    Alopecia (all grade)41%21%
    Ocular surface events (grade 1, dry eye/keratitis)24%3%
    ILD/pneumonitis (drug-related, adjudicated)Less than 1%Less than 1%
    Hematologic toxicity (neutropenia, anemia)Lower than chemo armPredominant toxicity

    Several aspects of this safety data are worth emphasizing for clinical context. First, discontinuation due to treatment-related adverse events was actually lower with Dato-DXd (4%) than with chemotherapy (7%). This means patients on the experimental arm were less likely to stop treatment because of toxicity despite the higher overall rate of any adverse event. The profile is different, not simply worse.

    Second, stomatitis at 57% is high in absolute terms but predominantly low-grade. The OncLive panel reviewing these results noted that proactive oral care management, including steroid-based mouthwash protocols (expanded from the SWISH trial experience with everolimus), can substantially reduce the incidence and severity of high-grade stomatitis. Institutions implementing Dato-DXd will need nursing education focused on stomatitis prevention and grading.

    Third, ocular surface events (dry eye, keratitis) at 24% are almost entirely grade 1 and manageable with lubricating eye drops and ophthalmologic monitoring. The ILD rate of less than 1% is consistent with the known Dato-DXd class signal, lower than what is seen with T-DXd at current doses. ILD monitoring, prompt evaluation of respiratory symptoms, and early intervention with corticosteroids for confirmed cases remain important clinical requirements.

    Context: How This Fits Into the TNBC Treatment Landscape

    If approved, Dato-DXd would become the first non-chemotherapy, non-immunotherapy first-line option for metastatic TNBC patients who cannot receive checkpoint inhibitors. The treatment landscape for this population would shift in two meaningful ways.

    First, the starting line for subsequent treatment sequencing changes. Patients who progress on first-line Dato-DXd will have had an ADC with a specific toxicity profile and resistance pattern. How sacituzumab govitecan (Trodelvy), currently approved in previously treated metastatic TNBC, performs after Dato-DXd progression is not established. This sequencing question will drive post-approval research.

    Second, the ADC revolution in breast cancer treatment is now reaching the TNBC immunotherapy-ineligible population specifically. T-DXd reshaped HER2-positive and HER2-low metastatic breast cancer. Sacituzumab govitecan improved outcomes in previously treated TNBC. Dato-DXd, if approved, would extend ADC-based first-line treatment into a subgroup previously limited to cytotoxic chemotherapy.

    What the TROPION-Breast01 trial (HR+/HER2- breast cancer) can teach us here Dato-DXd’s January 2025 FDA approval for HR-positive, HER2-negative metastatic breast cancer came from the TROPION-Breast01 trial. That trial met its primary PFS endpoint but did not achieve statistical significance on OS. The explanation offered by investigators was that subsequent ADC treatment in the control arm after disease progression may have equalized survival outcomes. TROPION-Breast02 in TNBC is different in a clinically important way: it achieved statistical significance on both PFS and OS. This distinction matters for the regulatory submission and for clinician confidence. When a trial achieves the survival endpoint and not just the surrogate, the benefit-risk assessment is on firmer ground. The difference in OS outcomes between the two trials also highlights how patient population and available subsequent therapies shape survival data. TNBC patients in TROPION-Breast02 had fewer subsequent treatment options after progression compared to HR+ patients, which may have allowed the OS benefit to emerge more clearly in this trial.

    What to Discuss With Your Oncologist Now

    What This Approval Means for Patients With Immunotherapy-Ineligible Metastatic TNBC

    Datroway is now FDA-approved and available for this population

    Datroway (datopotamab deruxtecan-dlnk) is now an FDA-approved first-line option for adults with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy. It is the first and only targeted therapy approved in this setting and the first to demonstrate a statistically significant OS advantage over chemotherapy in this population.

    NCCN guidelines have been updated following the approval: Datroway is now listed as a Category 1 preferred first-line treatment option for immunotherapy-ineligible metastatic TNBC. Oncologists at NCCN member institutions will begin prescribing based on this recommendation immediately.

    Understanding the accelerated approval pathway

    The FDA approved the TNBC indication under accelerated approval, using objective response rate (ORR) and duration of response as the regulatory endpoints. The ORR with Datroway was 63% versus 29% with chemotherapy, and median duration of response was 12.3 versus 7.1 months. These are the formal bases for the approval.

    This is important context for patients and clinicians. Accelerated approval means the FDA determined that the ORR and duration of response data were sufficiently compelling to authorize use now, while a confirmatory trial verifies long-term clinical benefit. The PFS (10.8 vs. 5.6 months) and OS (23.7 vs. 18.7 months) data from TROPION-Breast02 strongly support the treatment’s value but are not the formal regulatory basis for this approval.

    Continued approval may be contingent upon the outcome of the confirmatory trial. This does not mean the drug will be removed from the market; it means AstraZeneca and Daiichi Sankyo must verify the clinical benefit findings as the follow-up matures.

    What to discuss with your oncologist now

    • Has your tumor been tested for PD-L1 expression? If your tumor is PD-L1 positive and you have no contraindications to immunotherapy, pembrolizumab plus chemotherapy remains the approved standard of care.
    • If you are not a PD-1/PD-L1 candidate, Datroway is now an FDA-authorized first-line option you can discuss with your oncologist as an alternative to standard cytotoxic chemotherapy.
    • Ask about stomatitis prevention protocols and ocular monitoring, which are the key toxicity management considerations with Datroway.
    • Ask whether your oncology center has experience with Datroway from the TROPION-Breast02 trial enrollment or from the HR+/HER2- TNBC approval earlier in 2025.
    • If you are enrolled in or considering a clinical trial involving Datroway, discuss how this approval affects your options with your treating oncologist.

    Global availability

    For patients outside the United States: Datroway has not yet been approved by the EMA, Health Canada, PMDA (Japan), or TGA (Australia) for the TNBC indication. Regulatory submissions are under review in multiple markets. Check the most current status with your oncologist or the national regulatory authority in your country.

    For patients and families navigating a TNBC diagnosis, the Triple Negative Breast Cancer Foundation, Susan G. Komen, and the National Cancer Institute Cancer Center directory continue to be the best starting points for treatment resources, clinical trial information, and support programs.

    Sources

    Primary publication: Dent RA, Shao Z, Schmid P, et al. Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial. Annals of Oncology. 2026 Apr 3. doi:10.1016/j.annonc.2026.03.008. PubMed PMID: 41937088.

    OncLive Phase 3 results: TROPION-Breast02 Data Support Dato-DXd as New First-Line SOC in Triple-Negative Breast Cancer. OncLive. April 2026.

    OncLive Priority Review: FDA Grants Priority Review to Frontline Dato-DXd for Metastatic TNBC Ineligible for Immunotherapy. OncLive. 2026.

    OncLive panel discussion: Findings for Frontline Dato-DXd From TROPION-Breast02 in Immunotherapy-Ineligible TNBC. OncLive. May 2026.

    OncoDaily safety summary: Datopotamab Deruxtecan Improves PFS and OS in First-Line Advanced TNBC in TROPION-Breast02. OncoDaily. April 2026.

    Cancer Nursing Today: Datopotamab Deruxtecan Expands First-Line Treatment Options in Metastatic TNBC. May 2026.

    CancerNetwork overview: How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research. CancerNetwork. May 2026.

    AstraZeneca Priority Review announcement: DATROWAY granted Priority Review in the US as 1st-line treatment for patients with metastatic TNBC who are not candidates for immunotherapy. AstraZeneca. 2026.

    TROPION-Breast01 context: FDA approves datopotamab deruxtecan for HR+/HER2- breast cancer. FDA.gov. January 2025.

    Patient resources: NCI Cancer Center directory | Susan G. Komen | TNBC Foundation

    FDA approval announcement: FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic triple-negative breast cancer. FDA.gov. May 22, 2026.

    AstraZeneca/Daiichi Sankyo press release: DATROWAY approved in the US as first TROP2-directed ADC for 1st-line treatment of patients with metastatic TNBC. businesswire.com. May 22, 2026.

    PharmExec approval coverage: FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates. pharmexec.com. May 2026.

    AJMC approval coverage: Datopotamab Deruxtecan Wins First-Line FDA Approval for Immunotherapy-Ineligible Triple-Negative Breast Cancer. ajmc.com. May 2026.

    Healio approval coverage: Datroway nabs FDA approval for immunotherapy-ineligible triple-negative breast cancer. healio.com. May 2026.

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. The TNBC indication for Datroway was approved under accelerated approval; continued approval may be contingent upon confirmatory trial results. Treatment decisions for metastatic TNBC should be made in close consultation with a qualified oncologist who can account for your individual diagnosis, treatment history, and tumor biology.

  • The Combination Acne Gel Dermatologists Have Prescribed for 15 Years Is Now Available Without a Prescription.

    The Combination Acne Gel Dermatologists Have Prescribed for 15 Years Is Now Available Without a Prescription.

    📌 The essentials On May 22, 2026, the FDA approved Differin Epiduo Acne Gel (adapalene 0.1% and benzoyl peroxide 2.5%, Galderma) for over-the-counter (OTC) use in adults and adolescents aged 12 years and older for the treatment of acne. This is a prescription-to-OTC switch. The product was previously available only with a dermatologist prescription. Retail availability: most major retailers including Walmart, Ulta, Target, and Amazon, beginning summer 2026. The clinical basis: more than 10 randomized, controlled Phase 3 clinical trials involving over 3,200 patients, plus more than 15 years of real-world prescription use. The combination gel consistently outperformed adapalene alone, benzoyl peroxide alone, and vehicle gel across inflammatory lesions, noninflammatory lesions, total lesion counts, and Investigator Global Assessment success rates. Inflammatory lesion reductions observed as early as week 1; up to 70.3% reduction in inflammatory lesions by week 12. Sustained efficacy demonstrated through 12 months of use. What makes this a meaningful access change: adapalene 0.1% plus benzoyl peroxide 2.5% is a guideline-recommended, first-line acne combination. Access was previously limited to patients with insurance coverage or the ability to afford a dermatology visit. This switch removes that barrier.

    Acne vulgaris is not a minor skin concern. It affects approximately 85% of people between ages 12 and 24 in the United States and persists into adulthood for a significant proportion. Beyond the physical manifestations, acne carries a well-documented psychological burden: studies consistently link moderate to severe acne with depression, anxiety, and reduced quality of life, particularly in adolescents and young adults. And yet, first-line prescription acne treatments have historically required an appointment with a dermatologist, a specialist with a median wait time of more than 30 days in many U.S. markets.

    The gap between when patients want treatment and when they can access effective treatment has been one of the persistent frustrations of acne care.

    On May 22, 2026, the FDA addressed one piece of that gap: it approved Differin Epiduo Acne Gel (adapalene 0.1% and benzoyl peroxide 2.5%) for over-the-counter use in patients aged 12 and older, making a combination that dermatologists have been prescribing for more than 15 years available at the drugstore without a visit to a clinic.

    This is not a watered-down consumer version of an effective drug. It is the same formulation, the same concentrations, and the same once-daily application that generated more than 10 randomized controlled trials and millions of prescriptions. The only thing that changed is that you no longer need a prescription to buy it.

    What Makes This Combination Different From Standard OTC Acne Products

    The drugstore acne aisle is full of products. Most of them contain one of three active ingredients: benzoyl peroxide, salicylic acid, or adapalene 0.1% (which became OTC in the United States in 2016). Understanding why the combination of adapalene and benzoyl peroxide is a step above either alone requires understanding what causes acne and what each ingredient addresses.

    The four drivers of acne vulgaris

    Acne is a multifactorial disease driven by four interconnected processes:

    Excess sebum production: The sebaceous glands produce more oil than the skin can manage, creating an environment that supports the growth of acne-causing bacteria.

    Follicular hyperkeratinization: Dead skin cells inside the hair follicle do not shed normally, causing the cells to accumulate and block the pore. This is what produces a comedone (clogged pore), which is the precursor to both whiteheads (closed comedones) and blackheads (open comedones).

    Propionibacterium acnes (now reclassified as Cutibacterium acnes) overgrowth: The bacteria that live on skin and inside follicles proliferate in the sebum-rich, low-oxygen environment of a blocked pore, triggering inflammatory responses.

    Inflammation: The immune system’s response to bacterial antigens inside the follicle produces the characteristic redness, swelling, and pain of inflammatory acne lesions (papules, pustules, nodules).

    No single-ingredient product addresses all four of these processes. This is precisely why dermatology guidelines have long recommended combination therapy as the standard of care.

    What adapalene does

    Adapalene is a third-generation synthetic retinoid developed by Galderma specifically to address the stability and tolerability limitations of earlier topical retinoids like tretinoin. Unlike tretinoin, adapalene is photostable and chemically stable, which matters for formulation: it can be combined with other active ingredients (including benzoyl peroxide) in a single product without degrading.

    Adapalene works at the cellular level by binding to specific retinoic acid receptors (RARs) in skin cells. By modulating gene expression in keratinocytes (the cells that line follicles), it normalizes the keratinization process, preventing the follicular plugging that leads to comedones. It also has direct anti-inflammatory activity. Adapalene is widely regarded as the best-tolerated topical retinoid available: it causes significantly less dryness, peeling, and redness than tretinoin at comparable efficacy, particularly early in treatment.

    What benzoyl peroxide does

    Benzoyl peroxide (BPO) is an oxidizing agent that releases free radicals in the skin, directly killing Cutibacterium acnes bacteria by degrading their cell membranes. It has been a cornerstone of acne therapy for decades. Critically, BPO does not cause bacterial resistance, unlike topical antibiotics such as clindamycin, where resistance has become a significant clinical problem. At 2.5%, the concentration in Differin Epiduo, research has shown comparable antibacterial efficacy to higher concentrations (5% and 10%) with a substantially better tolerability profile.

    Why the combination outperforms either ingredient alone

    The synergy between adapalene and BPO is mechanistic and well-documented. Adapalene normalizes follicular keratinization and reduces inflammation, creating a less obstructed skin environment. BPO eliminates the bacteria that drive inflammatory lesion development. Together, they address both the comedonal (non-inflammatory) and inflammatory components of acne through independent and complementary pathways.

    In multiple randomized controlled trials comparing adapalene/BPO gel to adapalene monotherapy, BPO monotherapy, and vehicle gel, the combination consistently outperformed all three comparators on every efficacy measure: inflammatory lesions, noninflammatory lesions, total lesions, and IGA success rates. The combination also produced faster onset, with lesion reductions detectable as early as week 1 of treatment.

    What the Investigator Global Assessment (IGA) measures The Investigator Global Assessment is the standard five-point scale used in acne clinical trials to assess overall acne severity: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe. In clinical trials, an “IGA success” is typically defined as achieving a score of 0 (clear) or 1 (almost clear) with at least a 2-grade improvement from baseline. For most patients entering trials at IGA 3 (moderate), IGA success means moving from moderate acne to clear or almost-clear skin. This endpoint captures what patients actually care about: overall appearance, not just lesion counts. The combination adapalene/BPO gel achieved higher IGA success rates in pivotal trials than adapalene or BPO alone.

    The Clinical Evidence: More Than 10 Trials and 3,200 Patients

    The FDA’s approval of Differin Epiduo for OTC use is supported by one of the most extensive clinical evidence packages ever assembled for an acne product. Galderma cited more than ten Galderma-sponsored randomized controlled Phase 3 studies involving more than 3,200 patients, plus substantial third-party research, covering a wide range of ages, skin tones, and acne severity levels.

    The core efficacy story from that dataset:

    OutcomeResult (adapalene/BPO vs. vehicle)
    Inflammatory lesion reduction by week 12Up to 70.3% with combination vs. substantially lower with vehicle
    Noninflammatory lesion reduction by week 12Significant superiority over both monotherapies and vehicle
    IGA success rate (clear or almost clear)Higher with combination than adapalene alone, BPO alone, or vehicle
    Onset of efficacyDetectable as early as week 1
    DurabilitySustained efficacy demonstrated through 12 months
    Combination vs. adapalene aloneSuperior on inflammatory lesions, IGA success, total lesion count
    Combination vs. BPO aloneSuperior on noninflammatory lesions, IGA success, total lesion count

    Source: Galderma Phase 3 clinical program. Thiboutot DM et al. J Am Acad Dermatol. 2007. Multiple published trials. Presented by Galderma at FDA NDA and OTC switch submissions.

    The 70.3% reduction in inflammatory lesions at week 12 is a clinically significant number. Inflammatory lesions (papules, pustules) are the acne manifestations that cause pain, scarring risk, and the greatest psychosocial impact. Reducing them by nearly three-quarters over 12 weeks of once-daily application, at a concentration that is well tolerated, is what established this product as a first-line agent in dermatology practice.

    The long-term data through 12 months is particularly relevant for the OTC setting, where sustained use without continued prescriber oversight is the norm. The evidence indicates that the efficacy is maintained over months of use, not just in the initial weeks.

    Why Guideline-Concordant Acne Treatment Has Been Inaccessible

    The American Academy of Dermatology (AAD) guidelines for acne and the Global Alliance to Improve Outcomes in Acne both recommend topical retinoid plus benzoyl peroxide combinations as a first-line, guideline-preferred approach for mild to moderate acne. Adapalene/BPO is specifically named in clinical guidelines as a preferred dual-active regimen.

    Despite this guideline support, the combination has been behind the prescription barrier until now. This matters for several overlapping reasons.

    Dermatologist access: An estimated one-third of Americans lack access to a dermatologist within a reasonable distance from their home. Rural and underserved urban areas are particularly affected. Patients in these areas have historically been limited to products available OTC, which until this approval did not include a retinoid/BPO combination at guideline-recommended concentrations.

    Cost of care: A dermatology visit for acne, without insurance coverage, typically runs $100 to $250 for an initial consultation. For uninsured or underinsured adolescents and young adults, this is a significant barrier. Prescription co-pays for Epiduo with insurance have historically ranged widely, and without insurance, the prescription price could run over $200 per tube.

    Prescription gap for patients who improve: Even patients who see a dermatologist and get a prescription face ongoing friction: refill appointments, pharmacy trips, and the possibility of insurance changes affecting coverage. OTC availability removes these recurring barriers for sustained use.

    The skin tone gap in acne care: Post-inflammatory hyperpigmentation (PIH), the dark marks left after acne lesions resolve, is more prevalent and more severe in patients with darker skin tones. Adapalene has documented evidence of reducing PIH as part of its normalization of cell turnover, making consistent access to a retinoid-containing product particularly meaningful for patients with skin of color who experience this complication disproportionately.

    The Prescription-to-OTC Switch Process: What the FDA Reviews

    A prescription-to-OTC switch is not simply a label change. It requires a separate FDA regulatory review demonstrating that:

    • The drug can be used safely and effectively by consumers without physician supervision
    • The indication, dosing instructions, and labeling are understandable to lay consumers
    • The drug’s benefits outweigh its risks in the self-use context
    • Long-term safety data support unsupervised use

    The FDA’s review of the Differin Epiduo OTC switch drew on more than 15 years of prescription use safety data, a global safety database including millions of prescriptions, and the consumer use clinical program. The approval for ages 12 and older reflects confidence that the product can be used safely and effectively by adolescents as well as adults in a self-directed context.

    How to Use Differin Epiduo: What the Label Covers

    Differin Epiduo Acne Gel is intended for once-daily use, applied as a thin layer to the entire acne-affected area, not just to individual spots. This is an important and commonly misunderstood instruction: spot-treating active lesions misses the comedonal component of acne developing just below the surface.

    Key application instructions:

    • Apply a thin layer to the affected area once daily in the evening, after washing and gently drying the skin
    • Use your fingertips to apply a pea-sized amount for the entire face; a larger amount for the back, chest, or other areas
    • Wash hands immediately after applying
    • Allow to dry completely before applying moisturizer or other products on top
    • Avoid contact with eyes, lips, and mucous membranes; if contact occurs, rinse thoroughly with water

    What to expect:

    Weeks 1 to 4 often bring a temporary “adjustment period” of mild skin dryness, redness, or peeling as the skin adapts to retinoid use. This is normal and typically resolves with continued use. Starting with every-other-day application for the first 1 to 2 weeks can reduce early irritation.

    Sun protection: Adapalene-containing products increase photosensitivity. Use broad-spectrum SPF 30 or higher sunscreen daily during treatment and limit sun exposure. Do not apply immediately before sun exposure.

    Moisturizer: Using a non-comedogenic moisturizer daily helps manage dryness and improve tolerability, especially during the adjustment period.

    Warnings and who should not use it

    • Do not use if you are allergic to adapalene or benzoyl peroxide
    • Avoid contact with bleachable fabrics (towels, pillowcases, clothing): benzoyl peroxide bleaches fabric
    • Discontinue and consult a healthcare provider if severe irritation, allergic reaction, or significant worsening occurs
    • Pregnancy: adapalene is in FDA pregnancy category C for topical use. Animal data suggests potential risk. The systemic absorption from topical application is minimal, but out of an abundance of caution, consult a healthcare provider before use during pregnancy or breastfeeding
    • For the youngest eligible users (ages 12 to 15): a parent or guardian should supervise initial use to ensure correct application technique and sun protection compliance

    Where Differin Epiduo Fits in the OTC Acne Landscape

    Until this approval, the OTC landscape for combination acne therapy was limited. Here is how Differin Epiduo compares to what was already available:

    OTC product typeActive ingredientsMechanismGuideline status
    Benzoyl peroxide alone (2.5%, 5%, 10%)BPOAntimicrobialGuideline-recommended; available OTC for decades
    Salicylic acid (0.5% to 2%)Beta-hydroxy acidMild keratolyticUseful for mild comedonal acne; less evidence for inflammatory lesions
    Adapalene 0.1% gel (Differin)AdapaleneRetinoidGuideline-recommended; OTC since 2016
    Differin Epiduo Acne Gel (new)Adapalene 0.1% plus BPO 2.5%Retinoid plus antimicrobialGuideline-recommended first-line combination; now OTC

    The arrival of the combination gel completes the adapalene-based OTC acne care ladder: monotherapy adapalene 0.1% for mild comedonal acne, combination adapalene/BPO 0.1/2.5% for mild to moderate inflammatory and mixed acne, and a dermatologist pathway for severe, nodular, or treatment-resistant disease.

    For Patients: Practical Guidance

    This product is appropriate for:

    • Adults and adolescents aged 12 and older with mild to moderate acne, including both inflammatory (red, swollen pimples) and non-inflammatory (blackheads, whiteheads) lesions
    • People who have not had success with single-ingredient products
    • People who previously used Epiduo by prescription and want to continue without the prescription barrier
    • People who want a guideline-concordant first-line treatment without a clinic visit

    This product is not appropriate as a standalone treatment for:

    • Nodular or cystic acne (large, deep, painful lesions), which requires dermatologist care
    • Severe acne with significant scarring risk
    • Acne unresponsive to OTC treatment after 12 weeks of consistent use

    When to see a dermatologist: If your acne has not improved after 12 weeks of consistent daily use, if you develop nodules or cysts, if you have significant post-inflammatory dark marks (hyperpigmentation) that are not improving, or if your acne is causing significant psychological distress, a dermatology consultation is appropriate. The AAD’s Find a Dermatologist tool can help locate a board-certified dermatologist. For those with limited access to in-person care, several telehealth dermatology platforms provide prescription acne treatment via video or asynchronous consultation.

    For a related HED post covering the icotrokinra (ICOTYDE) approval as another step toward effective skin condition treatment options, see our post on the first oral IL-23 receptor blocker for psoriasis.

    Sources

    FDA approval news: FDA Approves Differin Epiduo Acne Gel (adapalene/benzoyl peroxide) for Nonprescription Use in the Treatment of Acne. Drugs.com. May 24, 2026.

    Galderma press release: Galderma Receives U.S. FDA Approval for Differin Epiduo Acne Gel Prescription-to-OTC Switch. businesswire.com. May 22, 2026.

    Galderma website announcement: Galderma Receives U.S. FDA Approval for Differin Epiduo Acne Gel Prescription-to-OTC Switch. galderma.com. May 22, 2026.

    Practical Dermatology clinical coverage: FDA Approves OTC Switch for Galderma’s Differin Epiduo Acne Gel. practicaldermatology.com. May 2026.

    The Dermatology Digest clinical coverage: US FDA Approves Prescription-to-OTC Switch for Differin Epiduo Acne Gel. thedermdigest.com. May 2026.

    Drugs.com approval history: Differin Epiduo Acne Gel FDA Approval History. drugs.com.

    Pivotal combination trial (JAAD 2007): Thiboutot DM et al. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: Results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol. 2007.

    AAD acne guidelines: American Academy of Dermatology. Guidelines of care for the management of acne vulgaris. aad.org.

    Acne biology and pathophysiology: Acne Vulgaris. StatPearls. NCBI.

    Adapalene mechanism: Adapalene. StatPearls. NCBI.

    Benzoyl peroxide mechanism: Benzoyl Peroxide. StatPearls. NCBI.

    Retinoid receptor biology: Retinoids in Dermatology. PMC4756869.

    IGA scale validation: Investigator Global Assessment in Acne. PMC5300780.

    Global Alliance acne guidelines: Global Alliance to Improve Outcomes in Acne. PMC7374761.

    Patient resources: AAD: What Is Acne? | AAD Find a Dermatologist | National Eczema Association (for skin barrier support)

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Patients with severe, nodular, or cystic acne, those who are pregnant or breastfeeding, and those whose acne does not respond to OTC treatment after 12 weeks should consult a board-certified dermatologist.
  • AML in Older Adults Has Been Treated With IV Infusions for Years. The FDA Just Approved the First All-Oral Alternative.

    AML in Older Adults Has Been Treated With IV Infusions for Years. The FDA Just Approved the First All-Oral Alternative.

    📌 The essentials On May 13, 2026, the FDA approved Inqovi (decitabine and cedazuridine, Taiho Oncology) in combination with venetoclax for adults with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude intensive induction chemotherapy. This is Inqovi’s third FDA-approved indication, joining myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML), both approved in 2020. What makes it first-in-class: Inqovi plus venetoclax is the first and only all-oral hypomethylating agent (HMA) plus BCL-2 inhibitor combination approved in any cancer setting. The previous standard of care for this population, azacitidine plus venetoclax (Venclexta), requires intravenous or subcutaneous azacitidine injections. The clinical basis: Phase 2b ASCERTAIN-V trial (NCT04657081), 101 adults with newly diagnosed AML ineligible for intensive chemotherapy. CR rate: 46.5% (95% CI 36.5 to 56.7%). CR/CRi rate: 63.4%. Median time to CR: 2.4 months. 75.3% of CR patients maintained remission at 12 months. Median OS: 15.5 months (95% CI 7.6 to not estimable). Safety: Grade 3 or higher adverse events in 98% of patients, consistent with known HMA/BCL-2 inhibitor class profile; febrile neutropenia, anemia, and neutropenia most frequent; no new drug-drug interaction signals. Dosing: Inqovi (35 mg decitabine / 100 mg cedazuridine) orally on days 1 to 5 of each 28-day cycle, with venetoclax 400 mg daily after cycle 1 ramp-up. All oral. No clinic infusion required.

    Acute myeloid leukemia is among the most challenging blood cancers to treat. It is diagnosed in an estimated 22,720 Americans in 2026, and it has an uncomfortable demographic reality: it predominantly affects older adults, with a median diagnosis age of approximately 68 years. The same patients who are most likely to develop AML are often the least able to tolerate the treatment that offers the best chance of remission, intensive induction chemotherapy involving days of hospitalization, profound bone marrow suppression, and significant mortality risk even when the treatment works.

    For older adults and those with significant comorbidities, the established approach over the past five years has been a less intensive regimen of azacitidine or decitabine, both given by injection or infusion, combined with venetoclax (Venclexta, AbbVie/Genentech), an oral BCL-2 inhibitor. This HMA/BCL-2 combination transformed the treatment landscape for “unfit” AML patients after the pivotal VIALE-A trial, establishing remission rates and survival outcomes that were meaningfully better than HMA alone.

    The problem is the parenteral component. Azacitidine requires injections or infusions on 7 days of every 28-day cycle, meaning patients must come to a clinic or have a home health nurse administer the drug regularly throughout treatment. For a 78-year-old with heart failure, limited mobility, or inadequate transport, this creates a real and sometimes insurmountable access barrier.

    On May 13, 2026, the FDA approved a solution to that access problem: Inqovi (decitabine and cedazuridine) plus venetoclax, an all-oral alternative that achieves equivalent drug exposure to intravenous decitabine through a pharmacological workaround, administered entirely at home.

    What Inqovi Is and the Problem It Was Designed to Solve

    Inqovi is a fixed-dose combination tablet containing two drugs: decitabine and cedazuridine. Understanding why both are needed together requires understanding why oral decitabine alone does not work.

    Decitabine: the hypomethylating agent

    Decitabine is a nucleoside analog that works as a DNA hypomethylating agent (HMA). In cancer cells, abnormal DNA methylation silences tumor suppressor genes that would otherwise limit malignant growth. Decitabine incorporates into DNA and inhibits DNA methyltransferase (DNMT), reversing this silencing and restoring normal gene expression patterns. It is a well-established and effective anti-leukemia mechanism.

    The problem is delivery. Decitabine taken orally is rapidly broken down in the gut and liver by an enzyme called cytidine deaminase (CDA) before it can reach the bloodstream in therapeutic concentrations. This is why intravenous decitabine and subcutaneous azacitidine have been used for decades: bypassing the gastrointestinal route avoids this degradation.

    Cedazuridine: the CDA inhibitor that makes oral delivery work

    Cedazuridine is a selective inhibitor of cytidine deaminase in the gut and liver. When cedazuridine is co-administered with decitabine, it blocks the enzyme responsible for degrading decitabine in the gastrointestinal tract, allowing therapeutic concentrations of decitabine to be absorbed and to reach systemic circulation.

    Pharmacokinetic studies comparing oral Inqovi to IV decitabine 20 mg/m² demonstrated bioequivalent systemic exposure. The AUC (area under the concentration-time curve) for decitabine given as Inqovi matches IV decitabine, which was the key regulatory and clinical evidence establishing that the pill delivers the same drug at the same concentration as the infusion. This equivalence was demonstrated in the pivotal ASCERTAIN trial that supported Inqovi’s original 2020 approval for MDS and CMML.

    Venetoclax: the BCL-2 inhibitor that completes the combination

    Venetoclax (Venclexta) is an oral BCL-2 inhibitor that works through a completely distinct mechanism: it blocks the BCL-2 protein, which cancer cells overexpress to prevent their own programmed death (apoptosis). By blocking BCL-2, venetoclax restores the apoptotic pathway, causing AML cells to die. The synergy between HMA and BCL-2 inhibition is well-established: HMA therapy primes AML cells toward apoptosis, and venetoclax completes the process.

    Venetoclax has been oral since its approval. The barrier to an all-oral HMA/BCL-2 regimen was always the parenteral HMA component. Inqovi resolves that barrier.

    Why “all-oral” matters clinically beyond convenience The shift from intravenous azacitidine to oral Inqovi is not merely a quality-of-life upgrade, though quality of life matters significantly in older patients with AML. It has tangible clinical implications. Parenteral HMA regimens require 7 treatment days per cycle for azacitidine, meaning patients must arrange transportation to a clinic or home health services 7 times per month, often indefinitely. For a patient who lives alone, relies on others for transportation, or has mobility limitations from heart failure, pulmonary disease, or peripheral neuropathy, these logistical demands create real discontinuation risk. Studies in AML and MDS have documented that patients on parenteral HMA regimens miss doses or discontinue treatment earlier than protocol intent due to the burden of frequent clinic visits. An oral regimen administered at home on days 1 to 5 of a 28-day cycle eliminates these specific barriers entirely.

    AML in Patients Ineligible for Intensive Chemotherapy: Who Is This Population?

    The FDA-approved indication covers adults aged 75 or older, or adults with comorbidities that preclude intensive induction chemotherapy. This population has specific characteristics that make treatment selection different from younger, fit patients.

    Intensive induction chemotherapy for AML, typically the “7+3” regimen of cytarabine and anthracycline, is effective but produces profound myelosuppression (bone marrow suppression) and requires weeks of inpatient hospitalization. Early mortality rates with intensive therapy approach 10 to 15% in older patients, largely from infections and organ toxicity during the aplastic period. For a patient aged 75 with renal insufficiency, uncontrolled heart failure, or severe pulmonary disease, the risk of dying from the treatment may exceed the benefit.

    The ASCERTAIN-V trial population reflects this clinical reality: median age was 78 years, 51.5% had ECOG performance status of 1, and 16.8% had TP53 mutations (associated with particularly poor prognosis). The distribution across European LeukemiaNet (ELN) risk categories was: favorable 31.7%, intermediate 33.7%, adverse 29.7%, reflecting a realistic mix of disease risk rather than a cherry-picked low-risk population.

    The ASCERTAIN-V Trial: Full Results

    Design

    ASCERTAIN-V (NCT04657081) is an international, multicenter, open-label, single-arm, Phase 2 study. The Phase 2b portion enrolled 101 adults with newly diagnosed AML per WHO 2016 criteria, ECOG performance status 0 to 3, ineligible for intensive induction chemotherapy, with a life expectancy of at least 3 months.

    Dosing schedule per 28-day cycle:

    • Cycle 1 (venetoclax ramp-up): venetoclax 100 mg day 1, 200 mg day 2, 400 mg day 3 through day 28; Inqovi days 1 to 5
    • Cycle 2 onward: Inqovi days 1 to 5; venetoclax 400 mg daily

    Median follow-up at time of analysis: 11.2 months.

    Efficacy results

    OutcomeResult
    Complete remission (CR) rate46.5% (95% CI 36.5 to 56.7%)
    CR plus CRi (incomplete hematologic recovery) rate63.4% (95% CI 53.2 to 72.7%)
    CR plus CRh (partial hematologic recovery) rate51.5% (95% CI 41.3 to 61.6%)
    Median time to CR2.4 months
    Patients in CR at 6 months80.0%
    Patients in CR at 12 months75.3%
    Median duration of CRNot reached at time of analysis
    Median overall survival15.5 months (95% CI 7.6 to not estimable)

    Source: ASCERTAIN-V Phase 2b results. Presented at ASCO 2025 Annual Meeting and EHA Congress 2025. Taiho Oncology press release, May 13, 2026. NCT04657081.

    Contextualization against the standard of care

    The obvious benchmark is the VIALE-A trial, which established azacitidine plus venetoclax as the standard for unfit AML. VIALE-A produced a CR rate of 24.2% and a median OS of 14.7 months in the venetoclax arm. The ASCERTAIN-V CR rate of 46.5% and median OS of 15.5 months are directionally favorable, though cross-trial comparison must be interpreted with caution given differences in patient selection, trial design, and follow-up periods.

    Why cross-trial comparisons must be interpreted cautiously ASCERTAIN-V and VIALE-A enrolled patients using different criteria, at different time periods, in different geographic mixes of sites. ASCERTAIN-V’s single-arm design without a comparator arm means there is no concurrent control to account for evolving supportive care standards, referral patterns, or patient selection over time. The CR rates may also reflect different definitions or measurement timing. The appropriate conclusion from ASCERTAIN-V is that the all-oral combination achieves remission and survival outcomes consistent with published HMA/venetoclax benchmarks in this population, not that it is proven superior to azacitidine/venetoclax. A randomized confirmatory trial comparing the two approaches directly would be needed to establish superiority.

    Safety results

    Safety results from ASCERTAIN-V were consistent with the known profiles of both drugs in this class and in this patient population. These are not mild side effects: AML patients treated with HMA/BCL-2 inhibitor combinations experience significant myelosuppression, and the grade 3 or higher adverse event rate reflects this.

    Safety outcomeRate
    Grade 3 or higher adverse events (any)98.0% of patients
    Febrile neutropeniaMost common grade 3 or higher event
    Anemia (grade 3 or higher)Frequent
    Neutropenia (grade 3 or higher)Frequent
    Dose interruptions68.3%
    Discontinuations due to adverse events8.9%
    Fatal adverse events15.8% (3 attributed to adverse events, 10 to disease progression per 30/60-day mortality assessment)
    New drug-drug interactions (venetoclax/decitabine)None identified

    The 98% grade 3 or higher adverse event rate is alarming on first read but is consistent with what hematologists and patients should expect in AML treatment. Myelosuppression is inherent to HMA therapy in a disease characterized by dysfunctional bone marrow. The absence of new drug-drug interaction signals between oral decitabine and venetoclax (which was a theoretical concern given cedazuridine’s CDA inhibition affecting venetoclax metabolism) is an important safety finding.

    Venetoclax requires co-administration with a CYP3A4 inhibitor prophylaxis protocol during ramp-up. Patients on antifungal prophylaxis (such as posaconazole or fluconazole) need venetoclax dose reductions during ramp-up because these agents inhibit CYP3A4 and increase venetoclax exposure. Prescribers managing this combination must follow the venetoclax drug interaction tables carefully.

    Safety Warnings: What the Label Covers

    The Inqovi prescribing information includes important safety warnings that apply to the AML indication:

    Myelosuppression: Inqovi can cause severe myelosuppression in patients with AML, including fatal adverse reactions. Complete blood count monitoring before each treatment cycle and as clinically indicated is required.

    Differentiation syndrome: HMA agents and venetoclax can cause differentiation syndrome in AML, a potentially life-threatening inflammatory reaction caused by rapid differentiation of leukemic cells. Symptoms include fever, dyspnea, hypoxemia, rapid weight gain, and pleural or pericardial effusion. This is a medical emergency requiring corticosteroids and sometimes treatment interruption.

    Embryo-fetal toxicity: Inqovi can cause fetal harm. Females of reproductive potential should use effective contraception during treatment and for at least 6 months after the final dose. Males with female partners of reproductive potential should use effective contraception during treatment and for at least 3 months after the final dose. Breastfeeding should not occur during treatment and for at least 2 weeks after the final dose.

    Interactions with venetoclax: Strong or moderate CYP3A4 inhibitors increase venetoclax exposure and require dose adjustments. Avoid strong CYP3A4 inducers. The full venetoclax prescribing information and dose modification tables for drug interactions apply throughout the regimen.

    Dosing: The All-Oral Treatment Schedule

    The ASCERTAIN-V-based treatment schedule is:

    Cycle 1 (venetoclax ramp-up cycle):

    • Venetoclax: 100 mg on day 1, 200 mg on day 2, 400 mg on days 3 through 28
    • Inqovi (35 mg decitabine / 100 mg cedazuridine): one tablet orally once daily on days 1 to 5
    • Antifungal prophylaxis should accompany the venetoclax ramp-up per institutional protocol and the venetoclax prescribing information

    Cycles 2 and beyond (28-day cycles):

    • Inqovi: one tablet orally once daily on days 1 to 5
    • Venetoclax: 400 mg orally once daily on days 1 to 28 (or per dose modification per prescribing information)

    Inqovi tablets should be taken at approximately the same time each day. They can be taken with or without food. The tablet should be swallowed whole; do not cut, crush, or chew. If a dose is missed, it should be taken as soon as possible on the same day. If the day has passed, the missed dose should be skipped and the next dose taken at the regular scheduled time.

    Where This Approval Fits: Inqovi’s Full Indication Picture

    With this approval, Inqovi now carries three FDA-approved indications across blood cancers:

    IndicationDatePartner drug
    Myelodysplastic syndromes (MDS), including CMMLJuly 2020None (monotherapy)
    Newly diagnosed AML, intensive chemotherapy-ineligibleMay 13, 2026Venetoclax (Venclexta)

    The progression from MDS/CMML monotherapy to AML combination therapy reflects the well-established clinical overlap between these diseases. Many patients with high-risk MDS progress to AML, and the HMA mechanism is active across the disease spectrum. The ability to use the same oral drug platform in both MDS and AML simplifies the treatment transition for patients who progress from one to the other.

    For Patients and Caregivers

    Who qualifies?

    Adults newly diagnosed with AML who are either 75 years or older, or who have comorbidities (organ dysfunction, severe frailty, concurrent illness) that make intensive induction chemotherapy unsafe. This is not a designation based solely on age: younger patients with significant comorbidities may also qualify.

    What does all-oral treatment mean practically?

    The five-day Inqovi dosing window (days 1 to 5 of each cycle) combined with daily venetoclax means treatment is taken at home throughout each 28-day cycle. There is no scheduled infusion clinic requirement for the regimen itself. Blood count monitoring, toxicity assessment, and clinical follow-up still require clinic visits, but not for drug administration.

    This is a genuinely meaningful practical change for patients who live alone, lack reliable transportation, or have mobility limitations. The drug is given at home, and patients control their own administration schedule within the 5-day window.

    Questions to discuss with your hematologist

    • Do my specific AML genetics (cytogenetics, molecular markers) suggest I am likely to respond to an HMA/BCL-2 approach?
    • Should I be tested for TP53, FLT3, IDH1/2, or other mutations that might inform therapy selection?
    • How will venetoclax drug interactions with my current medications be managed, particularly if I am on antifungal prophylaxis?
    • What blood count monitoring schedule is appropriate for my regimen?
    • What are the early signs of differentiation syndrome and when should I call the oncology team?

    For patients and families navigating a new AML diagnosis, the Leukemia and Lymphoma Society provides patient-facing disease information, clinical trial databases, and financial assistance resources. AAMDSIF (Aplastic Anemia and MDS International Foundation) covers the full MDS and AML spectrum with educational materials specific to these diseases. The NCI AML information page provides current treatment guidance in patient-accessible language.

    For related coverage on venetoclax and its expanding role in blood cancers, including the first all-oral AML regimen and the Immgolis biosimilar approvals relevant to RA and UC, see our venetoclax coverage on Health Evidence Digest.

    Sources

    FDA approval announcement: FDA approves oral combination of decitabine and cedazuridine tablets with venetoclax for newly diagnosed acute myeloid leukemia. FDA.gov. May 13, 2026.

    Taiho Oncology press release: U.S. FDA Approves INQOVI in Combination with Venetoclax, the First All-Oral Combination Treatment for Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction Chemotherapy. businesswire.com. May 13, 2026.

    Cancer Therapy Advisor approval coverage: All-Oral Inqovi Regimen Approved for Newly Diagnosed AML. cancertherapyadvisor.com. May 2026.

    AJMC approval coverage: FDA Approves First All-Oral Regimen for AML. ajmc.com. May 2026.

    Targeted Oncology approval coverage: FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Unfit AML. targetedonc.com. May 2026.

    OncLive approval coverage: FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML. onclive.com. May 2026.

    CancerNetwork ASCO 2025 results: Oral Venetoclax Combo Elicits Responses, Survival in Newly Diagnosed AML. cancernetwork.com. 2025.

    AJMC ASCO 2025 summary: All-Oral AML Therapy: Decitabine-Cedazuridine Plus Venetoclax. ajmc.com. July 2025.

    ASCERTAIN-V trial registration: NCT04657081. ClinicalTrials.gov.

    Inqovi original MDS/CMML FDA approval: FDA approves decitabine and cedazuridine for treatment of adults with myelodysplastic syndromes. FDA.gov. July 2020.

    Venetoclax AML FDA approval: FDA approves venetoclax in combination for treatment of adults with newly diagnosed acute myeloid leukemia. FDA.gov.

    Decitabine mechanism: Decitabine. StatPearls. NCBI.

    DNA methylation and HMA therapy: DNA Hypomethylating Agents in Myeloid Malignancies. PMC4207474.

    Cedazuridine mechanism: Cedazuridine pharmacology. PMC7965890.

    BCL-2 and venetoclax: BCL-2 Inhibitors in Hematologic Malignancies. PMC8626879.

    AML overview: Acute Myeloid Leukemia. American Cancer Society.

    ASCO 2025 Annual Meeting: ASCO 2025 Annual Meeting. asco.org.

    EHA Congress 2025: EHA Congress 2025. ehaweb.org.

    Patient resources: Leukemia and Lymphoma Society | AAMDSIF | NCI AML Treatment (PDQ) | ClinicalTrials.gov: AML

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Treatment decisions for acute myeloid leukemia, including eligibility for intensive versus less intensive regimens, should be made in close consultation with a board-certified hematologist or hematologic oncologist familiar with the patient’s full disease characteristics, performance status, and comorbidity profile.
  • Fasenra Just Got a Third Approved Indication. Here Is What Hypereosinophilic Syndrome Is and What the NATRON Trial Data Actually Shows.

    Fasenra Just Got a Third Approved Indication. Here Is What Hypereosinophilic Syndrome Is and What the NATRON Trial Data Actually Shows.

    📌 The essentials On May 13, 2026, the FDA approved Fasenra (benralizumab, AstraZeneca) for the treatment of adults and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) without an identifiable non-hematologic secondary cause. This is Fasenra’s third FDA-approved indication, joining severe eosinophilic asthma (approved 2017) and eosinophilic granulomatosis with polyangiitis (EGPA, approved 2022). On May 21, 2026, the European Medicines Agency’s CHMP issued a positive opinion recommending EU approval of Fasenra for HES (as part of a label update also covering severe asthma and EGPA). The clinical basis: Phase 3 NATRON trial (NCT04191304), published in Nature Medicine on March 31, 2026, enrolling 133 patients with HES (67 benralizumab, 66 placebo), 24 weeks, randomized double-blind placebo-controlled. Primary endpoint: 65% reduction in risk of first HES flare (HR 0.35; 95% CI 0.18 to 0.69; p=0.0024). All secondary endpoints met, including 66% reduction in annualized flare rate (0.41 versus 1.23 flares/year), 92% reduction in risk of hematologic relapse (HR 0.08; p less than 0.0001), and significant improvement in patient-reported fatigue by week 4. Dosing: 30 mg subcutaneous injection once every 4 weeks (different from the loading dose schedule used in asthma). Fasenra is the second anti-eosinophil biologic approved for HES, after mepolizumab (Nucala, approved 2020).

    Hypereosinophilic syndrome (HES) is a condition most people have never heard of. Most primary care providers encounter it rarely if at all. And for the approximately 30,000 to 200,000 Americans estimated to be living with it, that relative unfamiliarity often means years of unexplained symptoms, difficult diagnoses, and limited treatment options.

    On May 13, 2026, the FDA approved Fasenra (benralizumab) for HES, making it the second targeted biologic approved for this rare condition and the first approved for patients as young as 12. The pivotal trial behind the approval, NATRON, was published in Nature Medicine and met all of its endpoints, including a clinically meaningful reduction in flares, a striking near-elimination of hematologic relapse risk, and the first statistically significant improvement in fatigue ever demonstrated in a Phase 3 HES trial.

    This post covers what HES is and why it is hard to diagnose and treat, how benralizumab works, what every NATRON endpoint showed, and what this approval means for patients and clinicians navigating this condition.

    What Hypereosinophilic Syndrome Is

    Eosinophils are a type of white blood cell that normally account for less than 5% of circulating leukocytes. They are part of the immune system’s response to parasitic infections and play a role in allergic inflammation. In healthy adults, the normal eosinophil count is below 500 cells per microliter of blood.

    HES is defined by three criteria: a blood eosinophil count of 1,500 cells per microliter or higher, persisting for more than one month; evidence of eosinophil-mediated organ or tissue damage; and exclusion of identifiable secondary causes for the eosinophilia.

    When eosinophils are persistently elevated and activated, they infiltrate tissues throughout the body and release toxic granule proteins that damage the organs they contact. The damage is cumulative and organ-agnostic: any tissue can be affected. The most common sites of involvement include the lungs, skin, gastrointestinal tract, and heart. Eosinophilic heart disease, including Loeffler endocarditis, is one of the most serious and potentially fatal complications, with thrombus formation, valvular damage, and restrictive cardiomyopathy all documented.

    HES is not one disease: the subtypes matter clinically HES is a heterogeneous group of disorders, not a single entity. The classification includes: myeloproliferative HES, driven by a clonal eosinophil proliferation (the FIP1L1::PDGFRA fusion gene is the most common driver); lymphocytic variant HES, where an abnormal T-cell clone produces excess IL-5; idiopathic HES, where no underlying driver is identified; familial HES; and HES associated with other conditions. The NATRON trial specifically excluded patients with FIP1L1::PDGFRA-positive myeloproliferative HES, because those patients typically respond to imatinib (a tyrosine kinase inhibitor) and represent a distinct pathophysiology. The trial also required patients to be corticosteroid-responsive. The approved indication similarly excludes patients with an identifiable non-hematologic secondary cause. Clinicians should confirm these criteria before prescribing.

    HES is rare, with an estimated U.S. prevalence of 0.3 to 6.3 cases per 100,000 persons, but the true prevalence is likely underestimated due to diagnostic challenges. The condition can present with a wide and non-specific symptom spectrum: weight loss, fever, cough, chest pain, abdominal pain, skin rash, and neurological symptoms are all documented. Many patients spend years cycling through specialist consultations before a diagnosis is established. In the NATRON trial population, the mean time from first HES symptom appearance to enrollment was more than 8 years.

    The Disease Burden That NATRON Was Designed to Measure

    The NATRON trial population reflects what HES looks like in clinical practice. Of the 133 enrolled patients (median age 51, range 14 to 87 years, 61.7% female):

    • Most commonly involved organs were the lungs (35.6%), skin (25.3%), and gastrointestinal tract (21.8%)
    • 39.1% had experienced 2 HES flares in the prior 12 months; 36.8% had experienced 3 or more
    • Mean time since first HES symptoms was more than 8 years; mean time since diagnosis was nearly 5 years
    • Mean baseline PROMIS Fatigue T-score was 55.1, a score indicating clinically significant fatigue burden (population mean is 50; higher scores indicate worse fatigue)
    • Mean blood eosinophil count at baseline was 1,960 cells per microliter

    The flare definition used in NATRON is clinically meaningful: a flare required evidence of new or worsening HES clinical manifestations or laboratory abnormalities that resulted in hospitalization, or an increase in oral corticosteroid dose of at least 10 mg per day for at least 2 days, or the addition of new cytotoxic or immunosuppressive therapy. These are genuine clinical events with real consequences, not surrogate biomarker changes.

    How Benralizumab Works in HES

    Benralizumab is a humanized, afucosylated monoclonal antibody targeting the alpha subunit of the interleukin-5 receptor (IL-5Rα). IL-5 is the primary cytokine driving eosinophil production, maturation, survival, and activation. By binding IL-5Rα directly on eosinophils and their precursors (rather than binding the IL-5 ligand itself, as mepolizumab does), benralizumab triggers antibody-dependent cell-mediated cytotoxicity (ADCC) through natural killer cells, producing rapid and near-complete depletion of blood and tissue eosinophils within days of the first injection.

    The afucosylation engineering is the key pharmacological innovation that distinguishes benralizumab from mepolizumab within the anti-IL-5 class. By removing a fucose sugar from the antibody’s Fc region, the modified antibody binds Fc-gamma receptor IIIa on NK cells with much higher affinity, dramatically enhancing the ADCC-driven cell killing. This mechanism produces a more rapid and more complete eosinophil depletion than IL-5 ligand blocking alone.

    In HES, the downstream consequence of this eosinophil depletion is reduced tissue infiltration, less release of eosinophil granule proteins that damage organs, and a lower risk of the inflammatory flares that drive clinical worsening and organ damage. The NATRON data confirms that this biological effect translates to clinically meaningful outcomes.

    The NATRON Trial: All the Numbers

    Design

    NATRON (NCT04191304) was a Phase 3, multicenter, randomized, double-blind, placebo-controlled study. Eligible patients were aged 12 years and older, FIP1L1::PDGFRA-negative, with HES flare signs or symptoms at screening or at least 2 flares in the prior year, and confirmed corticosteroid-responsive disease. Patients were randomized 1:1 to benralizumab 30 mg or placebo subcutaneously every 4 weeks, on top of stable background HES therapy, for a 24-week double-blind treatment period.

    Primary endpoint

    OutcomeBenralizumab (n=67)Placebo (n=66)
    Patients with first HES flare19.4%42.4%
    Risk of first flare (HR)0.35 (95% CI 0.18 to 0.69)Reference
    p-value0.0024—
    Flare risk reduction65%—

    The primary endpoint was met with a hazard ratio of 0.35, meaning patients on benralizumab had only 35% of the flare risk of placebo-treated patients. The Kaplan-Meier curves separated early and continued to diverge, with benralizumab-treated patients maintaining lower flare risk throughout the 24-week observation period.

    Key secondary endpoints (all statistically significant)

    OutcomeBenralizumabPlaceboEffect size and significance
    Proportion with HES flares22.4%45.5%OR 0.31 (95% CI 0.14 to 0.69); p=0.0033
    Annualized flare rate0.41 flares/year1.23 flares/yearRR 0.34 (95% CI 0.18 to 0.63); p=0.0008
    Risk of hematologic relapseHR 0.08 (95% CI 0.03 to 0.20)Referencep less than 0.0001; 92% risk reduction
    PROMIS Fatigue improvement at Week 24LS mean difference vs placebo: −4.72Reference95% CI −7.64 to −1.80; p=0.0017
    Fatigue improvement onsetBy Week 4—Sustained to Week 24

    Source: Ogbogu PU, Roufosse F, Akuthota P, et al. Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nat Med. Published online March 31, 2026. doi:10.1038/s41591-026-04315-8. NATRON NCT04191304.

    The hematologic relapse endpoint, defined as blood eosinophil count rising above 1,000 cells per microliter after confirmed depletion, showed a 92% risk reduction with benralizumab. This near-elimination of hematologic relapse reflects the drug’s mechanism: near-complete eosinophil depletion from the first dose, sustained throughout the dosing period.

    The fatigue endpoint is clinically important and worth highlighting. HES-related fatigue is one of the most commonly reported and most disabling symptoms in the condition. The NATRON PROMIS Fatigue results are the first statistically significant improvement in patient-reported fatigue from a Phase 3 HES trial. The fact that the improvement was detectable by week 4, after just the first monthly injection, and sustained to week 24, is a meaningful signal that the biological effect is rapid and durable.

    What PROMIS Fatigue measures and why a difference of 4.72 points is clinically meaningful The PROMIS (Patient-Reported Outcomes Measurement Information System) Fatigue Short Form 7a is a validated, standardized questionnaire assessing fatigue severity and impact over the previous 7 days. Scores are T-scored to a general population mean of 50, with higher scores indicating worse fatigue. The NATRON population had a mean baseline score of 55.1, indicating a clinically significant fatigue burden above population norms. A difference of 4.72 points is consistent with published minimally important difference thresholds for PROMIS Fatigue in chronic disease populations, generally estimated at 4 to 6 points. The improvement therefore exceeds the threshold for clinical meaningfulness, not just statistical significance.

    Safety

    The safety profile of benralizumab in NATRON was consistent with its well-established profile from seven years of use in severe asthma. Crucially, the overall adverse event rate was similar between groups: 64.2% in the benralizumab arm versus 66.7% with placebo, and serious adverse events occurred at virtually identical rates (7.5% versus 7.6%). This parity in overall adverse event burden, combined with a substantially better efficacy profile, is what the FDA reviewed in establishing a favorable benefit-risk balance.

    The most common adverse reactions in the HES population (occurring in 5% or more of benralizumab-treated patients and more frequently than placebo) were headache, hypersensitivity reactions (including urticaria, papular urticaria, and rash), and influenza-like illness. The adolescent patients (aged 12 to 17) in the trial had safety and tolerability results consistent with adults.

    Where Benralizumab Fits in HES Treatment

    Before discussing how benralizumab fits into HES management, it is worth acknowledging that the treatment landscape for HES remains relatively underdeveloped compared to more common eosinophilic conditions.

    The standard treatment for HES has historically been high-dose oral corticosteroids, which effectively suppress eosinophils and reduce symptoms but carry well-known long-term toxicity including osteoporosis, weight gain, diabetes, infections, and adrenal suppression. Patients on chronic steroids for HES accumulate organ damage from both the disease and the treatment.

    Imatinib (Gleevec) is the first-line agent for FIP1L1::PDGFRA-positive myeloproliferative HES, which is excluded from both the Fasenra and Nucala approvals.

    Mepolizumab (Nucala, GSK) was approved for HES in adults in 2020, as the first targeted anti-IL-5 agent for this indication, based on the Phase 3 EXPLORER trial showing a 50% reduction in the risk of HES worsening.

    Benralizumab now adds a second biologic option, with a 65% flare risk reduction and the additional advantages of near-complete eosinophil depletion (versus partial reduction with mepolizumab), once-monthly dosing throughout treatment (versus monthly loading then quarterly dosing with mepolizumab after the first three doses), and a pediatric indication down to age 12 (mepolizumab is approved for adults only in HES).

    Benralizumab vs. mepolizumab in HES: what the data comparison suggests No head-to-head trial comparing benralizumab and mepolizumab in HES has been conducted, and cross-trial comparisons are methodologically unreliable. The EXPLORER trial (mepolizumab) enrolled 108 patients and showed 50% reduction in HES worsening; NATRON enrolled 133 patients and showed 65% reduction in flare risk. The patient populations, flare definitions, and time periods differed in ways that make numerical comparison inappropriate. What is appropriate to note is that both drugs reduce eosinophils via the IL-5 pathway and both have demonstrated meaningful clinical benefit in HES. The mechanistic distinction (receptor blockade with direct eosinophil depletion versus ligand blockade with partial reduction) may matter more in individual patients with high eosinophil burden or disease that is incompletely controlled on mepolizumab. The choice between them will ultimately depend on prescriber experience, patient-specific factors, and in some cases prior response to one agent.

    Dosing: An Important Difference From the Asthma and EGPA Schedule

    Clinicians already prescribing Fasenra for severe asthma or EGPA should note that the dosing schedule for HES is different.

    For severe asthma: 30 mg every 4 weeks for the first 3 doses, then 30 mg every 8 weeks thereafter.

    For EGPA and HES: 30 mg once every 4 weeks throughout treatment. No switch to an every-8-week schedule.

    This distinction matters for prescription writing, patient counseling, and specialty pharmacy dispensing. Patients should receive a clear explanation that their dosing schedule differs from what they may have read about Fasenra in the asthma context.

    Administration: subcutaneous injection into the upper arm, thigh, or abdomen. Can be administered by a healthcare provider or by self-injection after proper training.

    What Patients and Caregivers Should Know

    Who is this approval for?

    Adults and pediatric patients aged 12 years and older with HES that does not have an identifiable non-hematologic secondary cause, and specifically FIP1L1::PDGFRA-negative disease. If you have been diagnosed with HES and are currently managing the condition with oral corticosteroids or other systemic therapies with inadequate control or significant side effects, Fasenra is now an FDA-authorized option to discuss with your hematologist or allergist-immunologist.

    When to involve a specialist

    HES is a rare condition that requires specialist expertise for accurate diagnosis and management. Hematologists, allergist-immunologists, and in some cases rheumatologists or pulmonologists depending on organ involvement are the specialists most experienced with HES diagnosis and treatment. Because the condition is rare, specialized centers with multi-disciplinary eosinophilia programs (several are affiliated with academic medical centers in the United States) often have the most experience with the full diagnostic workup, including genetic testing for FIP1L1::PDGFRA and lymphocytic variant HES markers.

    Patient support

    The American Partnership for Eosinophilic Disorders (APFED) is the primary patient advocacy organization for eosinophilic conditions in the United States and maintains updated resources on HES including a specialist referral network. The Hypereosinophilic Syndrome Research Program at NIH through the National Institute of Allergy and Infectious Diseases has been a leading center for HES research and may have open clinical trials. The National Organization for Rare Disorders (NORD) maintains a current clinical overview of HES.

    For related HED coverage on other biologic approvals in eosinophilic conditions, see our post on Trimbow, the first single-inhaler triple therapy for uncontrolled asthma, and our post on Fasenra’s companion indication in EGPA and the broader role of anti-IL-5 biologics in eosinophilic inflammation.

    Sources

    FDA approval announcement: FDA approves benralizumab (Fasenra) for hypereosinophilic syndrome. FDA.gov. May 13, 2026.

    AstraZeneca US press release: FASENRA approved in US for hypereosinophilic syndrome. astrazeneca-us.com. May 14, 2026.

    NATRON primary publication (Nature Medicine): Ogbogu PU, Roufosse F, Akuthota P, et al. Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nat Med. Published online March 31, 2026. doi:10.1038/s41591-026-04315-8.

    NATRON ACAAI 2025 abstract (Annals of Allergy): Benralizumab for patients with hypereosinophilic syndrome: A randomized, double-blind, placebo-controlled phase 3 trial (NATRON). Ann Allergy Asthma Immunol. November 2025.

    NATRON full results (AstraZeneca press release, November 2025): Statistically significant NATRON Phase III trial results for hypereosinophilic syndrome show Fasenra delayed time to first flare. astrazeneca.com.

    NATRON trial registration: NCT04191304. ClinicalTrials.gov.

    EMA CHMP positive opinion (May 21, 2026): Fasenra. EMA. ema.europa.eu.

    PharmExec FDA approval coverage: FDA Approves Fasenra for Hypereosinophilic Syndrome. pharmexec.com. May 2026.

    Pulmonology Advisor NATRON coverage: Add-On Benralizumab Effective in Hypereosinophilic Syndrome. pulmonologyadvisor.com.

    NATRON design paper (Blood/ASH 2023): The Phase 3 NATRON Study Evaluating Benralizumab in Patients with Hypereosinophilic Syndrome: Study Design and Patient Characteristics. Blood. 2023.

    HES GARD overview: Hypereosinophilic Syndrome. rarediseases.info.nih.gov.

    HES StatPearls: Hypereosinophilic Syndrome. StatPearls. NCBI.

    Eosinophil biology: Eosinophils. StatPearls. NCBI.

    Benralizumab mechanism (afucosylation and ADCC): Anti-IL-5 and IL-5Rα biologics: mechanisms and clinical evidence. PMC7186825.

    Eosinophilic heart disease: Cardiac Manifestations in Hypereosinophilic Syndrome. PMC5454610.

    Mepolizumab HES FDA approval: FDA approves mepolizumab for treatment of hypereosinophilic syndrome. FDA.gov.

    PROMIS Fatigue instrument: PROMIS Adult Measures: Fatigue. healthmeasures.net.

    Corticosteroids overview: Corticosteroids. StatPearls. NCBI.

    Fasenra prescribing information: FASENRA (benralizumab) Prescribing Information. AstraZeneca. 2026.

    Patient resources: American Partnership for Eosinophilic Disorders (APFED) | NIH HES Research Program (NIAID) | NORD: Hypereosinophilic Syndrome | ClinicalTrials.gov: HES

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Hypereosinophilic syndrome requires accurate diagnosis and specialist management. Treatment decisions should be made in consultation with a qualified allergist-immunologist or hematologist experienced in eosinophilic conditions.

healthevidencedigest